MeSH term
Frequency | Condition_Probility | Female | 599 | 0.0 |
Humans | 2203 | 0.0 |
Pregnancy | 49 | 0.0 |
Randomized Controlled Trials | 2 | 0.0 |
Adolescent | 161 | 0.0 |
Adult | 537 | 0.0 |
Aged | 293 | 0.0 |
Child | 102 | 0.0 |
Child, Preschool | 63 | 0.0 |
Infant | 54 | 0.0 |
Male | 572 | 0.0 |
Middle Aged | 442 | 0.0 |
Cardiac Output, Low/*mortality | 3 | 5.0 |
Coronary Arteriosclerosis/mortality | 3 | 5.0 |
Risk | 5 | 0.0 |
Surgical Procedures, Elective/*mortality | 3 | 5.0 |
Time Factors | 116 | 1.0 |
Aged, 80 and over | 78 | 0.0 |
Balloon Dilatation/adverse effects/*instrumentation | 2 | 4.0 |
Esophageal and Gastric Varices/therapy | 2 | 4.0 |
Esophagus/*injuries/radiography | 2 | 4.0 |
Fatal Outcome | 8 | 1.0 |
Foreign Bodies/*radiography | 2 | 4.0 |
Gastrointestinal Hemorrhage/therapy | 2 | 4.0 |
*Medical Errors | 2 | 4.0 |
Pleural Cavity/*radiography | 2 | 4.0 |
Tomography, X-Ray Computed | 4 | 0.0 |
Animals | 423 | 0.0 |
Antineoplastic Agents/*pharmacology/therapeutic use | 2 | 2.0 |
DNA Damage | 3 | 0.0 |
Drug Resistance, Neoplasm | 4 | 0.0 |
Gene Expression | 39 | 0.0 |
Antibodies, Monoclonal/chemistry | 2 | 2.0 |
*Antigens, Neoplasm | 8 | 4.0 |
Immunohistochemistry | 113 | 0.0 |
Meningioma/*metabolism/pathology | 2 | 11.0 |
Prognosis | 63 | 1.0 |
Recurrence | 13 | 1.0 |
*Stents | 2 | 3.0 |
Swine | 9 | 0.0 |
Antineoplastic Agents/pharmacology | 4 | 0.0 |
Blotting, Western | 47 | 0.0 |
Cell Survival/drug effects | 19 | 1.0 |
Comparative Study | 230 | 0.0 |
Doxorubicin/pharmacology | 2 | 0.0 |
Drug Synergism | 28 | 2.0 |
K562 Cells | 5 | 1.0 |
Research Support, Non-U.S. Gov't | 1321 | 0.0 |
Verapamil/pharmacology | 2 | 2.0 |
Vincristine/pharmacology | 2 | 3.0 |
Receptors, Cell Surface/metabolism | 27 | 6.0 |
Tumor Necrosis Factor-alpha/metabolism | 40 | 5.0 |
Antigens, CD14/*metabolism | 75 | 89.0 |
Cell Separation | 54 | 5.0 |
Drug Interactions | 6 | 0.0 |
Interleukin-10/*pharmacology | 12 | 12.0 |
Interleukin-12/*biosynthesis | 2 | 5.0 |
Interleukin-18/biosynthesis | 2 | 33.0 |
Macrophage Colony-Stimulating Factor/*pharmacology | 10 | 25.0 |
Monocytes/*metabolism | 65 | 18.0 |
Receptors, IgE/metabolism | 3 | 9.0 |
Receptors, IgG/metabolism | 13 | 17.0 |
Antigens, CD/analysis | 150 | 9.0 |
Antigens, CD14/analysis | 73 | 62.0 |
Antigens, CD19/analysis | 4 | 4.0 |
Antigens, CD3/analysis | 11 | 4.0 |
Antigens, CD4/analysis | 7 | 1.0 |
Antigens, CD45/analysis | 11 | 4.0 |
Antigens, CD8/analysis | 8 | 3.0 |
Arthritis, Rheumatoid/*immunology | 10 | 4.0 |
Fluorescent Antibody Technique | 66 | 2.0 |
In Vitro | 125 | 2.0 |
Interferon Type II/analysis | 2 | 2.0 |
Receptors, Cell Surface/analysis/*metabolism | 2 | 25.0 |
Synovial Membrane/*cytology/immunology | 2 | 66.0 |
Antigen-Presenting Cells/physiology | 2 | 3.0 |
Antigens, CD40/analysis | 4 | 16.0 |
B-Lymphocytes/*immunology | 8 | 0.0 |
*Drosophila Proteins | 95 | 8.0 |
Fetus/*immunology | 5 | 10.0 |
Histocompatibility Antigens Class II/analysis | 11 | 5.0 |
Macrophage-1 Antigen/analysis | 14 | 31.0 |
Membrane Glycoproteins/analysis | 14 | 5.0 |
Monocytes/*immunology | 99 | 24.0 |
Pregnancy Trimester, Third | 2 | 1.0 |
Receptors, Cell Surface/analysis | 3 | 3.0 |
Research Support, U.S. Gov't, P.H.S. | 474 | 0.0 |
Cadaver | 2 | 0.0 |
Phenotype | 149 | 1.0 |
Antigens, CD14/*immunology | 44 | 88.0 |
Bacteria/*immunology | 5 | 29.0 |
Immunity, Natural/*immunology | 2 | 10.0 |
Lipopolysaccharides/*immunology | 23 | 30.0 |
Macrophage Activation | 25 | 14.0 |
Macrophages/*immunology | 35 | 14.0 |
Membrane Glycoproteins/*immunology | 3 | 1.0 |
Receptors, Cell Surface/*immunology | 5 | 6.0 |
Signal Transduction | 73 | 1.0 |
Antigens, CD14/*genetics | 35 | 97.0 |
Case-Control Studies | 48 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 56 | 1.0 |
Genotype | 37 | 0.0 |
Logistic Models | 4 | 0.0 |
*Polymorphism, Genetic | 36 | 0.0 |
Risk Factors | 17 | 0.0 |
Antigens, CD14/metabolism | 90 | 75.0 |
Apoptosis/*drug effects | 8 | 1.0 |
Bronchoalveolar Lavage Fluid/cytology | 12 | 10.0 |
In Situ Nick-End Labeling | 3 | 0.0 |
Lymphocyte Activation | 46 | 1.0 |
Base Sequence | 103 | 0.0 |
DNA Primers | 23 | 0.0 |
Endotoxins/toxicity | 2 | 11.0 |
Lipopolysaccharides/pharmacology | 111 | 11.0 |
*Promoter Regions (Genetics) | 13 | 0.0 |
Fibroblasts/immunology/metabolism/microbiology | 2 | 100.0 |
Lipopolysaccharides/*metabolism | 58 | 46.0 |
Membrane Glycoproteins/metabolism | 25 | 4.0 |
Calcium/metabolism | 14 | 0.0 |
Interleukin-8/*biosynthesis | 8 | 12.0 |
Tumor Necrosis Factor-alpha/*biosynthesis | 31 | 7.0 |
Analysis of Variance | 11 | 0.0 |
Flow Cytometry | 381 | 5.0 |
Leukocyte Count | 51 | 3.0 |
Longitudinal Studies | 6 | 0.0 |
Monocytes/cytology/*metabolism | 4 | 14.0 |
Thromboplastin/*metabolism | 6 | 3.0 |
Antigens, Surface | 4 | 7.0 |
Cell Differentiation/*physiology | 9 | 3.0 |
Cells, Cultured | 394 | 2.0 |
Collagenases/metabolism | 2 | 5.0 |
Enzyme Inhibitors/pharmacology | 20 | 0.0 |
Extracellular Matrix | 3 | 12.0 |
Monocytes/*cytology/metabolism | 7 | 29.0 |
Peroxidase/metabolism | 5 | 3.0 |
Cohort Studies | 8 | 0.0 |
Genetic Markers | 8 | 0.0 |
Predictive Value of Tests | 12 | 0.0 |
Prospective Studies | 33 | 0.0 |
Risk Assessment | 5 | 0.0 |
Leukocytes, Mononuclear/immunology/*metabolism | 2 | 13.0 |
Lipopolysaccharides/*immunology/pharmacology | 9 | 56.0 |
Neisseria meningitidis/*immunology | 4 | 23.0 |
Treatment Outcome | 25 | 0.0 |
Myocardial Infarction/*genetics | 3 | 7.0 |
Regression Analysis | 4 | 0.0 |
B-Lymphocytes | 4 | 2.0 |
T-Lymphocytes | 5 | 2.0 |
Lymphocytes/*immunology | 8 | 1.0 |
Mice | 197 | 0.0 |
NF-kappa B/drug effects/immunology | 2 | 66.0 |
Oligonucleotides, Antisense/*therapeutic use | 2 | 14.0 |
Antigens, CD11/metabolism | 3 | 15.0 |
Antirheumatic Agents/*pharmacology | 3 | 21.0 |
Apoptosis | 11 | 0.0 |
Calcitriol/pharmacology | 24 | 23.0 |
Cell Differentiation/drug effects/physiology | 6 | 6.0 |
Cell Division/drug effects | 73 | 2.0 |
Dose-Response Relationship, Drug | 69 | 1.0 |
Methotrexate/*pharmacology | 3 | 6.0 |
Monocytes/*drug effects/metabolism/pathology | 2 | 100.0 |
Tumor Cells, Cultured | 153 | 0.0 |
Antibodies, Monoclonal/immunology | 62 | 3.0 |
Antigens, Differentiation/*metabolism | 4 | 3.0 |
Cell Differentiation | 104 | 3.0 |
Dendritic Cells/*immunology | 23 | 9.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 48 | 12.0 |
Interleukin-4/pharmacology | 33 | 9.0 |
Interleukin-6/pharmacology | 8 | 2.0 |
Tumor Necrosis Factor-alpha/pharmacology | 36 | 3.0 |
Antigens, CD14/biosynthesis/*metabolism | 2 | 100.0 |
Monocytes/drug effects/metabolism | 10 | 11.0 |
Wegener's Granulomatosis/*metabolism | 2 | 66.0 |
Epithelium/immunology | 2 | 1.0 |
Hypersensitivity/*immunology | 3 | 6.0 |
Immune Tolerance | 8 | 2.0 |
Immunotherapy | 2 | 0.0 |
Antigens, Differentiation/genetics | 2 | 6.0 |
Antigens, Surface/genetics | 2 | 4.0 |
*Gene Expression | 3 | 0.0 |
Genetic Vectors | 10 | 0.0 |
Lipopolysaccharides/*pharmacology | 112 | 25.0 |
Membrane Glycoproteins/genetics/*physiology | 2 | 2.0 |
Mice, Inbred C3H | 23 | 3.0 |
Mice, Inbred C57BL | 24 | 0.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 7 | 1.0 |
Mitogen-Activated Protein Kinase 3 | 11 | 1.0 |
Mitogen-Activated Protein Kinases/metabolism | 11 | 1.0 |
NF-kappa B/*metabolism | 14 | 2.0 |
Oligonucleotide Array Sequence Analysis | 9 | 0.0 |
Receptors, Cell Surface/genetics/*physiology | 2 | 3.0 |
*Signal Transduction | 18 | 0.0 |
Transcription Factor AP-1/metabolism | 3 | 1.0 |
Cell Differentiation/*drug effects/physiology | 2 | 9.0 |
Up-Regulation/drug effects/physiology | 2 | 4.0 |
*Macrophage Activation | 12 | 21.0 |
Monocytes/*immunology/metabolism | 7 | 18.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 58 | 0.0 |
Cell Division | 45 | 1.0 |
Cell Line | 216 | 1.0 |
Cell Line, Transformed | 7 | 0.0 |
*Cell Transformation, Viral | 2 | 1.0 |
Chemokines/biosynthesis | 3 | 7.0 |
Phagocytosis | 42 | 10.0 |
Receptor, Macrophage Colony-Stimulating Factor/metabolism | 2 | 25.0 |
*Virus Latency | 2 | 4.0 |
Blood Transfusion | 2 | 1.0 |
Injury Severity Score | 2 | 5.0 |
Gene Expression/drug effects/physiology | 2 | 4.0 |
Antigens, CD14/immunology | 32 | 58.0 |
CHO Cells | 68 | 3.0 |
Hamsters | 71 | 1.0 |
Lymphocyte Activation/drug effects/*immunology | 2 | 4.0 |
Membrane Glycoproteins/drug effects/immunology | 2 | 40.0 |
Mitogen-Activated Protein Kinase 8 | 2 | 2.0 |
Receptors, Cell Surface/drug effects/immunology | 2 | 40.0 |
*Apoptosis | 16 | 1.0 |
CD4-Positive T-Lymphocytes/*virology | 2 | 2.0 |
Cloning, Molecular | 15 | 0.0 |
Transduction, Genetic | 4 | 1.0 |
Genes, Dominant | 2 | 0.0 |
Hela Cells | 10 | 0.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 11 | 3.0 |
Tissue Distribution | 4 | 0.0 |
Transfection | 76 | 0.0 |
Antibodies | 4 | 0.0 |
Acute Disease | 67 | 2.0 |
Antigens, Surface/*immunology | 8 | 5.0 |
Carrier Proteins/*immunology | 3 | 6.0 |
Chronic Disease | 19 | 1.0 |
Communicable Diseases/*immunology | 2 | 33.0 |
Immunity, Natural | 15 | 6.0 |
Antigens, CD/immunology/metabolism | 2 | 3.0 |
Antigens, CD14/*immunology/metabolism | 5 | 100.0 |
Antigens, Differentiation/immunology/metabolism | 2 | 22.0 |
Antigens, Differentiation, Myelomonocytic/immunology/metabolism | 3 | 42.0 |
Calgranulin A | 2 | 5.0 |
Histocompatibility Antigens Class II/metabolism | 6 | 7.0 |
Monocytes/cytology/*immunology/metabolism | 3 | 25.0 |
Alleles | 16 | 0.0 |
Homozygote | 7 | 0.0 |
Polymorphism, Genetic | 12 | 0.0 |
Actins/metabolism | 5 | 0.0 |
Antibodies, Monoclonal/metabolism | 9 | 2.0 |
Cell Adhesion | 53 | 3.0 |
Kinetics | 51 | 0.0 |
Membrane Glycoproteins/*metabolism | 29 | 5.0 |
RNA, Messenger/metabolism | 41 | 0.0 |
Receptors, Cell Surface/*metabolism | 29 | 5.0 |
Reverse Transcriptase Polymerase Chain Reaction | 63 | 0.0 |
T-Lymphocytes/*metabolism | 3 | 0.0 |
Teichoic Acids/*pharmacology | 5 | 20.0 |
*ADP-ribosyl Cyclase | 2 | 33.0 |
Amino Acid Chloromethyl Ketones/pharmacology | 3 | 2.0 |
*Antigens, CD | 16 | 2.0 |
Antigens, CD40/biosynthesis | 2 | 7.0 |
Cell Membrane/metabolism | 16 | 1.0 |
Cysteine Proteinase Inhibitors/pharmacology | 3 | 1.0 |
Down-Regulation/*immunology | 3 | 5.0 |
Gingiva/cytology/*immunology | 5 | 35.0 |
Lipopolysaccharides/immunology/pharmacology | 2 | 9.0 |
Membrane Glycoproteins/biosynthesis | 7 | 4.0 |
Porphyromonas gingivalis/*enzymology | 2 | 50.0 |
*Genetic Predisposition to Disease | 9 | 0.0 |
Promoter Regions (Genetics) | 15 | 0.0 |
Antigens, Surface/metabolism | 13 | 10.0 |
Gram-Negative Bacteria/*metabolism | 3 | 33.0 |
Lipopolysaccharides/metabolism | 32 | 28.0 |
Antibodies/pharmacology | 8 | 2.0 |
Arteriosclerosis/etiology | 2 | 2.0 |
Biological Markers/analysis | 28 | 3.0 |
Cell Adhesion Molecules/metabolism | 10 | 4.0 |
Inflammation/immunology | 7 | 6.0 |
Lipoproteins, LDL/metabolism | 3 | 1.0 |
Macrophages/metabolism | 18 | 5.0 |
Antigens, CD14/analysis/*immunology | 5 | 83.0 |
Blotting, Northern | 29 | 0.0 |
Colony Count, Microbial | 3 | 3.0 |
RNA, Messenger/analysis | 49 | 1.0 |
Karyotyping | 40 | 2.0 |
X Chromosome/*genetics | 2 | 0.0 |
Antigens, CD14/*analysis/blood | 3 | 100.0 |
Fetal Blood | 8 | 5.0 |
Hypersensitivity/*etiology | 3 | 37.0 |
Infant, Newborn | 52 | 1.0 |
Membrane Glycoproteins/genetics | 3 | 1.0 |
Milk, Human/*immunology | 2 | 13.0 |
Receptors, Cell Surface/genetics | 2 | 1.0 |
Solubility | 69 | 4.0 |
Antigens, CD34/metabolism | 3 | 1.0 |
Antigens, CD45/metabolism | 3 | 3.0 |
Biological Markers | 51 | 3.0 |
Microscopy, Electron | 30 | 1.0 |
*Neoplasm Proteins | 2 | 0.0 |
Antigens, CD14/*blood | 21 | 67.0 |
Endotoxins/*immunology | 5 | 41.0 |
Interleukin-1/*blood | 4 | 7.0 |
Pilot Projects | 4 | 0.0 |
Promoter Regions (Genetics)/genetics/immunology | 3 | 42.0 |
Sex Factors | 4 | 0.0 |
Statistics, Nonparametric | 20 | 1.0 |
Tumor Necrosis Factor-alpha/*metabolism | 7 | 1.0 |
Disability Evaluation | 2 | 5.0 |
Down-Regulation/*drug effects | 3 | 5.0 |
Receptors, Chemokine/*biosynthesis/genetics | 2 | 6.0 |
Cell Movement | 9 | 1.0 |
Antigens, CD/immunology | 33 | 6.0 |
Antigens, CD3 | 3 | 0.0 |
Antigens, CD80/immunology | 6 | 9.0 |
Cell Communication | 12 | 4.0 |
Interferon Type II/secretion | 3 | 2.0 |
Interleukin-12/immunology | 2 | 9.0 |
Lactobacillus/*immunology | 2 | 40.0 |
Membrane Glycoproteins/immunology | 15 | 8.0 |
Receptors, IgG/immunology | 3 | 8.0 |
Signal Transduction/*immunology | 13 | 3.0 |
Staphylococcus aureus/*immunology | 3 | 3.0 |
Lipopolysaccharides/immunology | 29 | 23.0 |
Molecular Sequence Data | 139 | 0.0 |
Monocytes/immunology | 60 | 16.0 |
Antigens, CD14/*biosynthesis/immunology | 2 | 100.0 |
Antigens, Differentiation, Myelomonocytic/*biosynthesis/immunology | 2 | 66.0 |
Monocytes/immunology/*metabolism | 10 | 20.0 |
Cellulose | 3 | 25.0 |
Leukocytes, Mononuclear/physiology | 3 | 10.0 |
Membranes, Artificial | 4 | 4.0 |
Renal Dialysis/*adverse effects | 5 | 3.0 |
Antigens, CD15 | 8 | 26.0 |
E-Selectin/metabolism | 4 | 8.0 |
Immunoenzyme Techniques | 54 | 1.0 |
Intercellular Adhesion Molecule-1/*metabolism | 5 | 9.0 |
Neutrophil Infiltration | 2 | 18.0 |
Up-Regulation | 49 | 2.0 |
Antigens, CD/metabolism | 58 | 6.0 |
Macrophages/cytology/metabolism | 2 | 8.0 |
Monocytes/cytology/metabolism | 5 | 19.0 |
Swine/*immunology | 5 | 15.0 |
Age Factors | 11 | 0.0 |
Antigens, CD/*biosynthesis/immunology | 3 | 12.0 |
Antigen Presentation | 25 | 8.0 |
Asthma/*immunology | 5 | 5.0 |
Hypersensitivity, Immediate/*immunology | 6 | 21.0 |
Immunophenotyping | 252 | 8.0 |
Cell Differentiation/*drug effects | 27 | 17.0 |
DNA-Binding Proteins/*metabolism | 6 | 0.0 |
Leukemia, Myeloid/metabolism/*pathology | 2 | 10.0 |
Proto-Oncogene Proteins/*metabolism | 3 | 0.0 |
Transcription Factors/*metabolism | 6 | 0.0 |
Tretinoin/*pharmacology | 12 | 3.0 |
Antigens, CD11b/metabolism | 2 | 18.0 |
Cell Adhesion Molecules/*metabolism | 9 | 3.0 |
Endothelium, Vascular/immunology | 3 | 7.0 |
Intercellular Adhesion Molecule-1/metabolism | 9 | 4.0 |
Leukocytes/immunology | 4 | 3.0 |
Vascular Cell Adhesion Molecule-1/metabolism | 2 | 2.0 |
Antigens, CD14/blood/*genetics/immunology | 2 | 100.0 |
Family | 3 | 0.0 |
Gene Frequency | 12 | 0.0 |
Genetic Predisposition to Disease | 10 | 0.0 |
Genetics, Population | 2 | 0.0 |
Immunoglobulin E/blood | 7 | 5.0 |
India/epidemiology | 2 | 2.0 |
Polymorphism, Genetic/*genetics/immunology | 3 | 50.0 |
Promoter Regions (Genetics)/*genetics/immunology | 2 | 66.0 |
Antigens, CD14/*analysis | 37 | 86.0 |
Probability | 5 | 0.0 |
Receptors, IgG/*analysis | 16 | 55.0 |
Reference Values | 29 | 0.0 |
Severity of Illness Index | 11 | 0.0 |
Antigens, CD/biosynthesis | 29 | 9.0 |
*Cell Differentiation | 10 | 4.0 |
English Abstract | 74 | 0.0 |
Goats | 2 | 2.0 |
Hematopoietic Stem Cell Transplantation | 4 | 2.0 |
Hematopoietic Stem Cells/*cytology/metabolism | 2 | 8.0 |
Transplantation, Heterologous | 4 | 0.0 |
Cytokines/blood | 9 | 4.0 |
Drug Therapy, Combination | 4 | 0.0 |
Lipopolysaccharides/blood | 6 | 28.0 |
Cytokines/immunology | 4 | 2.0 |
Disease Models, Animal | 9 | 0.0 |
Macrophages/immunology | 35 | 11.0 |
Neutrophils/immunology | 9 | 5.0 |
Reactive Oxygen Species/metabolism | 6 | 1.0 |
Virulence | 2 | 0.0 |
Peptidoglycan/metabolism | 2 | 28.0 |
Follow-Up Studies | 16 | 0.0 |
Incidence | 3 | 0.0 |
Polymerase Chain Reaction | 49 | 0.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
United States/epidemiology | 2 | 0.0 |
*Acute-Phase Proteins | 91 | 47.0 |
Antigens, CD14/physiology | 21 | 58.0 |
Carrier Proteins/genetics/physiology | 2 | 7.0 |
Cytokines/*biosynthesis/genetics | 5 | 7.0 |
*Gene Expression Regulation | 10 | 0.0 |
Interleukin-1/biosynthesis/genetics | 4 | 14.0 |
Leukocytes, Mononuclear/*metabolism | 10 | 7.0 |
Membrane Glycoproteins/deficiency/genetics/*physiology | 2 | 13.0 |
Mice, Knockout | 26 | 1.0 |
Receptors, Cell Surface/deficiency/genetics/*physiology | 2 | 13.0 |
Specific Pathogen-Free Organisms | 2 | 2.0 |
Tumor Necrosis Factor-alpha/biosynthesis/genetics | 7 | 11.0 |
Amino Acid Substitution | 2 | 0.0 |
Cell Adhesion/drug effects | 16 | 3.0 |
Cell Differentiation/drug effects | 130 | 12.0 |
Monocytes/*cytology/drug effects | 6 | 37.0 |
Mutation | 14 | 0.0 |
Protein Binding/physiology | 2 | 0.0 |
Signal Transduction/drug effects | 5 | 0.0 |
Antigens, CD14/biosynthesis | 42 | 66.0 |
Biological Transport | 8 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 16 | 0.0 |
Fibroblasts/metabolism | 5 | 0.0 |
Immunoblotting | 12 | 0.0 |
Microscopy, Fluorescence | 19 | 1.0 |
Monocytes/metabolism | 28 | 8.0 |
Peptides/chemistry | 4 | 1.0 |
Precipitin Tests | 23 | 0.0 |
Protein Structure, Tertiary | 10 | 0.0 |
Cell Survival | 15 | 1.0 |
Cytokines/*metabolism | 13 | 4.0 |
Dyes/pharmacology | 2 | 2.0 |
Interleukin-1/metabolism | 13 | 6.0 |
Antigens, CD/*analysis | 91 | 11.0 |
Immunoglobulin E/immunology | 4 | 6.0 |
Lipopolysaccharides/toxicity | 7 | 9.0 |
Th2 Cells/immunology | 4 | 2.0 |
Antibodies, Monoclonal/*therapeutic use | 6 | 1.0 |
Clinical Trials | 4 | 0.0 |
Endotoxins/immunology | 3 | 37.0 |
Tumor Necrosis Factor-alpha/immunology | 4 | 3.0 |
HLA-DR Antigens/metabolism | 14 | 9.0 |
T-Lymphocytes, Helper-Inducer/metabolism | 2 | 12.0 |
Antigens, CD4/blood | 5 | 8.0 |
Antiviral Agents/*therapeutic use | 2 | 1.0 |
Interleukin-1/blood | 4 | 2.0 |
Interleukin-6/blood | 12 | 2.0 |
Gram-Negative Bacteria/*pathogenicity | 2 | 100.0 |
HT29 Cells | 3 | 1.0 |
Lactobacillus/*physiology | 2 | 28.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 54 | 10.0 |
Nitric Oxide/physiology | 2 | 4.0 |
Cytokines/analysis | 4 | 5.0 |
*Hemoperfusion | 2 | 66.0 |
Cell Differentiation/immunology | 30 | 9.0 |
Gene Expression Regulation, Neoplastic | 7 | 0.0 |
*Immunophenotyping | 26 | 14.0 |
Leukemia, Myeloid/*immunology | 4 | 10.0 |
Proto-Oncogene Protein c-kit/metabolism | 2 | 4.0 |
Proto-Oncogene Proteins/metabolism | 3 | 0.0 |
Receptor Protein-Tyrosine Kinases/metabolism | 2 | 0.0 |
Antigens, CD14/genetics | 14 | 70.0 |
Interleukin-6/genetics | 6 | 8.0 |
*Kidney Transplantation | 6 | 1.0 |
Transplantation, Homologous | 10 | 1.0 |
Cytokines/secretion | 2 | 2.0 |
Gene Expression Profiling | 6 | 0.0 |
Gene Expression Regulation/*immunology | 3 | 2.0 |
Lymphocyte Activation/immunology | 14 | 2.0 |
Lymphocyte Culture Test, Mixed | 49 | 7.0 |
T-Lymphocytes/immunology | 41 | 2.0 |
Carcinogens/pharmacology | 3 | 3.0 |
Macrophage Activation/immunology | 8 | 21.0 |
Macrophages/cytology/immunology/*metabolism | 2 | 66.0 |
Recombinant Proteins/immunology/metabolism/pharmacology | 2 | 66.0 |
Tetradecanoylphorbol Acetate/pharmacology | 62 | 3.0 |
Tumor Necrosis Factor-alpha/*biosynthesis/immunology | 3 | 23.0 |
Gene Expression Regulation/drug effects | 14 | 1.0 |
Mice, Inbred BALB C | 29 | 0.0 |
RNA, Messenger/drug effects/genetics/metabolism | 2 | 2.0 |
Acute-Phase Reaction/blood | 3 | 16.0 |
Carrier Proteins/*blood | 3 | 1.0 |
*Membrane Glycoproteins | 105 | 11.0 |
Antibodies, Monoclonal/pharmacology | 30 | 4.0 |
Antigens, CD14/immunology/metabolism | 12 | 92.0 |
Antigens, CD18/immunology | 3 | 16.0 |
Cytokines/*biosynthesis | 32 | 8.0 |
Down-Regulation/drug effects/immunology | 2 | 10.0 |
Membrane Glycoproteins/*immunology/metabolism | 2 | 12.0 |
Receptors, Cell Surface/*immunology/metabolism | 2 | 14.0 |
Antigen-Presenting Cells/cytology | 2 | 25.0 |
Antigens, CD14/blood | 22 | 75.0 |
Antigens, CD34/*blood | 4 | 5.0 |
Cell Communication/physiology | 2 | 2.0 |
Cell Differentiation/physiology | 12 | 2.0 |
Cell Division/physiology | 6 | 0.0 |
Coculture Techniques | 21 | 3.0 |
Cytokines/pharmacology | 23 | 5.0 |
Dendritic Cells/*cytology/drug effects/metabolism | 2 | 66.0 |
*Fetal Blood | 2 | 4.0 |
Fibroblasts/*physiology | 2 | 3.0 |
Cell Membrane/immunology/metabolism | 4 | 3.0 |
Macrophage-1 Antigen/metabolism | 17 | 24.0 |
Models, Immunological | 6 | 2.0 |
Receptors, Cell Surface/immunology/metabolism | 3 | 20.0 |
Bacterial Infections/immunology | 2 | 8.0 |
Carrier Proteins/chemistry/physiology | 2 | 33.0 |
Collectins | 2 | 2.0 |
Lung/*immunology | 3 | 7.0 |
Macrophage-1 Antigen/*metabolism | 8 | 42.0 |
Renal Dialysis | 3 | 0.0 |
Annexin A5/metabolism | 4 | 4.0 |
Apoptosis/drug effects | 7 | 1.0 |
Cellulose/adverse effects/*analogs & derivatives | 2 | 50.0 |
Down-Regulation/drug effects | 11 | 4.0 |
Lipopolysaccharides/*toxicity | 18 | 31.0 |
Antigens, Differentiation/biosynthesis | 6 | 11.0 |
Cytoplasm/metabolism | 4 | 0.0 |
Enzyme Activation/physiology | 3 | 1.0 |
Signal Transduction/physiology | 6 | 0.0 |
Thromboplastin/metabolism | 2 | 2.0 |
Trans-Activators/*metabolism | 4 | 0.0 |
U937 Cells | 28 | 6.0 |
Drosophila | 2 | 0.0 |
*Immunity, Natural | 6 | 10.0 |
Macrophages/*immunology/physiology | 2 | 22.0 |
Mammals | 2 | 0.0 |
Fetal Blood/*immunology | 8 | 10.0 |
Gene Expression/immunology | 3 | 3.0 |
Interleukin-1/genetics | 7 | 10.0 |
Interleukin-8/genetics | 3 | 5.0 |
Sepsis/immunology | 5 | 41.0 |
Multivariate Analysis | 10 | 0.0 |
Antibiotics, Peptide/pharmacology | 4 | 14.0 |
Interleukin-1/*biosynthesis | 11 | 8.0 |
Interleukin-6/*biosynthesis | 9 | 8.0 |
Monocytes/cytology/drug effects/immunology | 4 | 40.0 |
Polymyxin B/pharmacology | 10 | 18.0 |
Australia | 2 | 1.0 |
Dendritic Cells/*metabolism | 4 | 6.0 |
HLA-D Antigens/biosynthesis | 3 | 27.0 |
T-Lymphocytes/metabolism | 4 | 1.0 |
Antigens, Differentiation/*biosynthesis | 3 | 9.0 |
Interferon Type II/*pharmacology | 19 | 4.0 |
RNA, Messenger/biosynthesis | 23 | 1.0 |
Receptors, Immunologic/*biosynthesis | 5 | 21.0 |
Occupational Exposure/*adverse effects | 2 | 2.0 |
Smoking/adverse effects | 2 | 0.0 |
Colony-Forming Units Assay | 13 | 2.0 |
Fetal Blood/*cytology | 11 | 5.0 |
Hematopoietic Stem Cells/*physiology | 4 | 3.0 |
*Lectins, C-Type | 12 | 7.0 |
Macrophages/*immunology/microbiology | 2 | 12.0 |
*Mannose-Binding Lectins | 10 | 20.0 |
Antibodies, Monoclonal/diagnostic use | 38 | 4.0 |
Leukocytes/*drug effects | 2 | 16.0 |
Lymphocyte Subsets | 10 | 5.0 |
Lymphocytes/drug effects | 2 | 2.0 |
Monocytes/drug effects | 8 | 15.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 14 | 2.0 |
Daunorubicin/administration & dosage | 4 | 11.0 |
Mitoxantrone/administration & dosage | 2 | 7.0 |
*Polyploidy | 3 | 11.0 |
RNA, Messenger/genetics | 29 | 1.0 |
RNA, Neoplasm/genetics | 2 | 0.0 |
Remission Induction | 15 | 2.0 |
Tumor Markers, Biological/genetics | 2 | 2.0 |
ADP-ribosyl Cyclase | 7 | 1.0 |
Antigens, CD/*analysis/genetics | 4 | 16.0 |
Antigens, Differentiation/analysis | 23 | 7.0 |
B-Lymphocyte Subsets/*immunology | 3 | 3.0 |
*Chromosome Aberrations | 6 | 1.0 |
Chromosome Deletion | 3 | 0.0 |
Chromosomes, Human, Pair 12 | 3 | 1.0 |
Cluster Analysis | 2 | 1.0 |
Leukemia, B-Cell, Chronic/genetics/*immunology | 2 | 25.0 |
NAD+ Nucleosidase/analysis | 2 | 4.0 |
Sequence Deletion | 5 | 0.0 |
Trisomy | 3 | 2.0 |
Tumor Stem Cells/*immunology | 4 | 17.0 |
*Cardiopulmonary Bypass/adverse effects | 2 | 25.0 |
Macrophages, Peritoneal/immunology/metabolism | 2 | 22.0 |
Membrane Glycoproteins/genetics/*metabolism | 7 | 4.0 |
Mice, Mutant Strains | 2 | 0.0 |
Monocytes/immunology/metabolism | 6 | 12.0 |
Postoperative Period | 4 | 1.0 |
Receptors, Cell Surface/genetics/*metabolism | 6 | 4.0 |
Immunosuppression | 6 | 3.0 |
Macrophages/drug effects/immunology/metabolism | 5 | 45.0 |
Phagocytosis/immunology | 7 | 10.0 |
Carrier Proteins/metabolism | 20 | 2.0 |
Interferon Type II/biosynthesis | 5 | 1.0 |
Interleukin-12/biosynthesis | 8 | 8.0 |
HL-60 Cells | 35 | 6.0 |
Ligands | 26 | 0.0 |
Epithelium/metabolism | 2 | 0.0 |
Integrins/analysis | 2 | 4.0 |
Interferon Type II/pharmacology | 25 | 4.0 |
Interleukin-1/*pharmacology | 4 | 0.0 |
Receptors, Interleukin/analysis | 2 | 18.0 |
Transcription, Genetic | 22 | 0.0 |
Antigens, CD/biosynthesis/*immunology | 2 | 10.0 |
Dendritic Cells/immunology/*pathology | 3 | 20.0 |
Monocytes/immunology/*pathology | 6 | 66.0 |
*Tumor Markers, Biological | 5 | 2.0 |
Fluorescence | 3 | 1.0 |
Caco-2 Cells | 4 | 1.0 |
Models, Biological | 24 | 0.0 |
Models, Chemical | 2 | 0.0 |
Permeability | 4 | 2.0 |
Software | 5 | 1.0 |
Macrophage Activation/*physiology | 5 | 21.0 |
Spleen/cytology | 7 | 4.0 |
Antibodies, Monoclonal | 88 | 3.0 |
Antigens, CD14/*blood/*genetics/immunology | 2 | 100.0 |
Chemiluminescent Measurements | 10 | 6.0 |
Chi-Square Distribution | 4 | 0.0 |
In Situ Hybridization, Fluorescence | 13 | 0.0 |
B-Lymphocytes/pathology | 2 | 2.0 |
*Cell Communication | 5 | 6.0 |
Leukocytes, Mononuclear/immunology/*pathology | 2 | 33.0 |
Antigens, CD14/*biosynthesis/genetics | 7 | 87.0 |
Calcitriol/*pharmacology | 28 | 15.0 |
Macrophages/physiology | 7 | 9.0 |
Membrane Glycoproteins/*biosynthesis/genetics | 2 | 3.0 |
Phagocytosis/drug effects | 17 | 20.0 |
Protein Kinase C/antagonists & inhibitors | 3 | 2.0 |
Receptors, Cell Surface/*biosynthesis/genetics | 3 | 13.0 |
Trans-Activation (Genetics) | 6 | 0.0 |
Tumor Necrosis Factor-alpha/secretion | 12 | 11.0 |
Antigens, CD14/*genetics/physiology | 3 | 75.0 |
Gene Expression Regulation | 30 | 0.0 |
Polymorphism, Single Nucleotide | 4 | 0.0 |
Homocysteine/*pharmacology | 2 | 13.0 |
Neutrophils/drug effects/metabolism | 2 | 6.0 |
Epithelial Cells/*immunology | 5 | 26.0 |
Lipopolysaccharides/immunology/metabolism | 4 | 50.0 |
RNA, Messenger/genetics/metabolism | 25 | 1.0 |
Inflammation Mediators/metabolism | 8 | 10.0 |
Bone Marrow Cells/*cytology | 7 | 14.0 |
Cell Size | 7 | 2.0 |
Endocytosis | 6 | 1.0 |
Leukocytes, Mononuclear/*cytology | 3 | 14.0 |
Integrin alphaXbeta2/*metabolism | 2 | 100.0 |
Macrophages, Alveolar/*metabolism | 4 | 13.0 |
*Phytotherapy | 3 | 3.0 |
Acetylcysteine/pharmacology | 2 | 2.0 |
Antigens, CD/biosynthesis/genetics | 4 | 11.0 |
Blood Physiology | 4 | 5.0 |
Cattle | 22 | 0.0 |
Culture Media, Serum-Free/pharmacology | 5 | 4.0 |
Cytokines/biosynthesis/genetics | 3 | 4.0 |
Genes, Reporter | 9 | 0.0 |
Monocytes/*cytology | 24 | 29.0 |
NF-kappa B/antagonists & inhibitors/metabolism | 2 | 6.0 |
Proto-Oncogene Proteins/biosynthesis/genetics | 2 | 2.0 |
Dactinomycin/pharmacology | 4 | 1.0 |
Interferon Type II/blood | 4 | 3.0 |
Neutrophils/*metabolism | 12 | 6.0 |
Receptors, Cell Surface/physiology | 6 | 5.0 |
Transcription, Genetic/drug effects | 7 | 1.0 |
Antigens, CD14/*biosynthesis | 13 | 86.0 |
DNA-Binding Proteins/metabolism | 7 | 0.0 |
Endotoxins/pharmacology | 4 | 5.0 |
Eosinophils | 2 | 5.0 |
*I-kappa B | 6 | 3.0 |
Phosphorylation | 27 | 0.0 |
Protein Binding | 45 | 0.0 |
Antigens, CD/genetics | 3 | 2.0 |
Cell Lineage | 19 | 4.0 |
Leukapheresis | 3 | 2.0 |
Lymphocyte Subsets/cytology/immunology | 2 | 22.0 |
Antigens, Neoplasm/metabolism | 4 | 5.0 |
Binding Sites/immunology | 3 | 5.0 |
Heat-Shock Proteins 70/metabolism | 2 | 3.0 |
Heat-Shock Proteins 90/metabolism | 2 | 6.0 |
Microscopy, Confocal | 7 | 0.0 |
Nitric Oxide/biosynthesis | 9 | 11.0 |
Protein Binding/immunology | 8 | 4.0 |
Cell Differentiation/drug effects/immunology | 11 | 15.0 |
Cytokines/*physiology | 2 | 1.0 |
Escherichia coli/immunology | 5 | 7.0 |
RNA, Messenger/*biosynthesis/metabolism | 2 | 16.0 |
Staphylococcus aureus/immunology | 6 | 5.0 |
Macrophages/drug effects/immunology/*metabolism | 2 | 28.0 |
Membrane Glycoproteins/*genetics | 8 | 1.0 |
Nitrites/metabolism | 4 | 9.0 |
Receptors, Cell Surface/*genetics | 10 | 3.0 |
Species Specificity | 19 | 0.0 |
Antigens, Differentiation, Myelomonocytic/analysis | 60 | 16.0 |
Monocytes/*metabolism/pathology | 2 | 28.0 |
Antigens, Neoplasm/immunology | 6 | 4.0 |
Dendritic Cells/*physiology | 4 | 5.0 |
*Immunotherapy | 2 | 1.0 |
Neoplasms/*therapy | 3 | 2.0 |
T-Lymphocytes, Cytotoxic/immunology | 7 | 1.0 |
Chromatography | 2 | 1.0 |
Chromatography, Gel | 4 | 0.0 |
Escherichia coli/metabolism | 9 | 3.0 |
Leukocytes/metabolism | 5 | 3.0 |
Lipopolysaccharides/*chemistry | 3 | 27.0 |
Neutrophils/metabolism | 5 | 3.0 |
Recombinant Proteins/metabolism | 23 | 0.0 |
Structure-Activity Relationship | 18 | 0.0 |
Neutrophil Activation/*physiology | 2 | 13.0 |
Phagocytosis/*physiology | 7 | 14.0 |
Respiratory Burst/*physiology | 2 | 20.0 |
Cell Culture Techniques | 22 | 4.0 |
Cell Cycle/drug effects | 15 | 2.0 |
Cell Division/*drug effects | 4 | 1.0 |
Fetal Blood/cytology | 16 | 8.0 |
Gene Expression/physiology | 2 | 0.0 |
Hematopoietic Stem Cells/*cytology/*immunology | 3 | 12.0 |
Retroviridae/genetics | 4 | 1.0 |
Antigens, CD/*analysis/biosynthesis | 2 | 16.0 |
Gestational Age | 7 | 0.0 |
Pregnancy/*immunology | 2 | 3.0 |
Antigens, CD14/*physiology | 40 | 85.0 |
Antigens, Differentiation, Myelomonocytic/chemistry/physiology | 2 | 100.0 |
Glycosylphosphatidylinositols/physiology | 3 | 42.0 |
Limulus Test | 3 | 13.0 |
Salmonella/immunology | 4 | 33.0 |
Shock, Septic/etiology/immunology | 2 | 50.0 |
Tumor Necrosis Factor-alpha/analysis | 14 | 3.0 |
Breast Feeding | 2 | 3.0 |
Antigens, CD14/biosynthesis/genetics | 4 | 57.0 |
Curcumin/pharmacology | 2 | 15.0 |
Interleukin-6/*biosynthesis/genetics | 3 | 8.0 |
Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors | 2 | 4.0 |
NF-kappa B/antagonists & inhibitors | 2 | 5.0 |
Thiocarbamates/pharmacology | 2 | 3.0 |
*Trans-Activation (Genetics) | 2 | 0.0 |
p38 Mitogen-Activated Protein Kinases | 18 | 2.0 |
Inflammation/metabolism | 3 | 3.0 |
Membrane Microdomains/*metabolism | 2 | 4.0 |
*Membrane Proteins | 14 | 1.0 |
Antigens, CD19/immunology | 2 | 5.0 |
Crohn Disease/*immunology | 3 | 7.0 |
Antigens, Surface/physiology | 2 | 5.0 |
Biological Factors/metabolism | 2 | 22.0 |
Membrane Glycoproteins/genetics/*metabolism/physiology | 2 | 28.0 |
Receptors, Cell Surface/genetics/*metabolism/physiology | 2 | 50.0 |
Streptococcus agalactiae/*physiology | 2 | 50.0 |
Acute-Phase Reaction | 2 | 4.0 |
Fluorescein-5-isothiocyanate | 19 | 13.0 |
Fluorescent Dyes | 9 | 2.0 |
Lipopolysaccharides/metabolism/*pharmacology | 15 | 62.0 |
Monocytes/*physiology | 22 | 14.0 |
Recombinant Proteins/pharmacology | 40 | 2.0 |
Sepsis/*blood | 3 | 15.0 |
Down-Regulation | 34 | 1.0 |
Endothelial Growth Factors/pharmacology | 3 | 2.0 |
Lipoproteins/*toxicity | 2 | 66.0 |
Lymphokines/pharmacology | 4 | 2.0 |
Vascular Endothelial Growth Factor A | 3 | 0.0 |
Vascular Endothelial Growth Factors | 3 | 0.0 |
*Genetic Vectors | 2 | 0.0 |
Macrophages/*drug effects | 3 | 13.0 |
Single-Blind Method | 2 | 0.0 |
Lipopolysaccharides/antagonists & inhibitors/*pharmacology | 6 | 33.0 |
Membrane Glycoproteins/genetics/metabolism/*physiology | 3 | 27.0 |
Reactive Oxygen Species/*metabolism | 5 | 3.0 |
Receptors, Cell Surface/genetics/metabolism/*physiology | 3 | 42.0 |
Antigens, CD14/*genetics/immunology | 4 | 80.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Platelet Glycoprotein GPIIb-IIIa Complex/drug effects/metabolism | 2 | 66.0 |
Body Weight | 2 | 0.0 |
Complement/metabolism | 3 | 3.0 |
Cytokines/*blood | 10 | 3.0 |
Germany | 3 | 0.0 |
*Heart-Assist Devices | 3 | 12.0 |
Survival Analysis | 19 | 0.0 |
Cytokines/genetics | 4 | 3.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 2 | 0.0 |
Gram-Negative Bacteria | 2 | 22.0 |
Enzyme-Linked Immunosorbent Assay/methods | 4 | 1.0 |
Antigens, CD/drug effects/metabolism | 2 | 18.0 |
Antigens, CD14/drug effects/metabolism | 2 | 66.0 |
Dextrans/pharmacokinetics | 2 | 40.0 |
Fluorescein-5-isothiocyanate/analogs & derivatives/pharmacokinetics | 2 | 100.0 |
Macrophages/chemistry | 4 | 16.0 |
Molecular Structure | 6 | 0.0 |
Receptors, Cell Surface/metabolism/physiology | 2 | 50.0 |
Tumor Cells, Cultured/drug effects | 5 | 0.0 |
Antigens, CD55/blood | 3 | 37.0 |
Clone Cells/immunology | 2 | 1.0 |
Erythrocytes/*immunology | 2 | 1.0 |
Flow Cytometry/*methods | 17 | 7.0 |
Culture Media | 16 | 2.0 |
Decidua/*cytology/immunology | 2 | 40.0 |
Antigens, CD34/*analysis | 12 | 4.0 |
Cell Count | 35 | 3.0 |
Granulocyte Colony-Stimulating Factor/*pharmacology | 10 | 8.0 |
HLA Antigens/analysis | 7 | 2.0 |
*Hematopoietic Stem Cell Transplantation | 7 | 1.0 |
Hematopoietic Stem Cells/*cytology/immunology | 7 | 8.0 |
Neutrophils | 2 | 2.0 |
Platelet Count | 5 | 1.0 |
Retrospective Studies | 7 | 0.0 |
Survival Rate | 18 | 0.0 |
Antigens, CD15/analysis | 4 | 14.0 |
*Cell Adhesion Molecules | 9 | 4.0 |
Cross-Sectional Studies | 15 | 1.0 |
Pregnancy/*blood | 6 | 3.0 |
Respiratory Burst | 11 | 17.0 |
Monocytes/immunology/*physiology | 4 | 25.0 |
Signal Transduction/immunology | 16 | 4.0 |
Recombinant Proteins/biosynthesis | 4 | 0.0 |
Antigens, Surface/genetics/metabolism/*physiology | 2 | 100.0 |
Glycosylation | 3 | 0.0 |
Mutagenesis, Site-Directed | 8 | 0.0 |
Antigens, CD14/isolation & purification | 3 | 60.0 |
Bacterial Proteins/*immunology | 2 | 6.0 |
Interleukin-8/biosynthesis | 8 | 7.0 |
NF-kappa B/metabolism | 34 | 4.0 |
Amino Acid Sequence | 63 | 0.0 |
*Antigens, CD14 | 2 | 40.0 |
Binding Sites | 28 | 0.0 |
Leukocytes, Mononuclear/immunology | 6 | 2.0 |
AIDS Dementia Complex/*immunology/pathology | 2 | 100.0 |
Cytokines/biosynthesis | 28 | 5.0 |
Dendritic Cells/*immunology/pathology | 2 | 11.0 |
Polymerase Chain Reaction/methods | 4 | 0.0 |
Antigens/metabolism | 4 | 6.0 |
Antigens, CD14/*analysis/immunology | 3 | 100.0 |
Chemotaxis | 3 | 1.0 |
Receptors, Chemokine/biosynthesis | 2 | 4.0 |
Skin/*immunology | 2 | 1.0 |
*Cardiopulmonary Bypass | 5 | 5.0 |
Double-Blind Method | 9 | 0.0 |
Glucocorticoids/*therapeutic use | 2 | 5.0 |
*Immunosuppression | 3 | 3.0 |
Inflammation/*drug therapy | 2 | 20.0 |
Preoperative Care | 2 | 1.0 |
*Polymorphism, Single Nucleotide | 3 | 0.0 |
Transcription Factor, Sp1/*metabolism | 2 | 0.0 |
Antigens, CD14/*genetics/metabolism | 5 | 83.0 |
Cytokines/metabolism | 21 | 4.0 |
DNA Primers/chemistry | 16 | 1.0 |
Membrane Glycoproteins/*genetics/metabolism | 4 | 5.0 |
Receptors, Cell Surface/*genetics/metabolism | 3 | 3.0 |
*Chromosome Deletion | 2 | 0.0 |
*Chromosomes, Human, Pair 11 | 4 | 0.0 |
Bacteria/pathogenicity | 2 | 100.0 |
Escherichia coli/*pathogenicity | 4 | 23.0 |
Interleukin-1/biosynthesis | 19 | 9.0 |
Interleukin-6/biosynthesis | 26 | 11.0 |
Porphyromonas gingivalis/*pathogenicity | 2 | 33.0 |
Escherichia coli/pathogenicity | 3 | 33.0 |
Leukocytes/physiology | 2 | 3.0 |
HIV-1/genetics | 2 | 3.0 |
Immunoglobulins/immunology | 4 | 8.0 |
Luciferases/genetics/metabolism | 2 | 0.0 |
Monocytes/*cytology/drug effects/immunology | 3 | 33.0 |
Recombinant Fusion Proteins/genetics/metabolism | 2 | 0.0 |
Antigens, CD34/*immunology | 4 | 5.0 |
Antigens, CD56/*immunology | 4 | 28.0 |
Antigens, Differentiation, Myelomonocytic/immunology | 13 | 27.0 |
Cell Differentiation/drug effects/*immunology | 3 | 37.0 |
Cell Proliferation/drug effects | 2 | 2.0 |
Cytotoxicity Tests, Immunologic | 6 | 1.0 |
Granulocyte Colony-Stimulating Factor/pharmacology | 12 | 7.0 |
Interleukin-2/pharmacology | 6 | 1.0 |
Lymphocyte Activation/drug effects/immunology | 4 | 6.0 |
Macrophages/cytology/drug effects/immunology | 2 | 66.0 |
Monocytes/cytology/drug effects/*immunology | 3 | 18.0 |
Serine Endopeptidases/metabolism | 2 | 1.0 |
Stem Cell Factor/pharmacology | 5 | 3.0 |
Antigens, CD14/immunology/*metabolism | 11 | 100.0 |
Brefeldin A/pharmacology | 2 | 2.0 |
Lipopolysaccharides/*immunology/*metabolism | 2 | 100.0 |
Membrane Glycoproteins/immunology/*metabolism | 4 | 9.0 |
Monocytes/*immunology/*metabolism | 3 | 20.0 |
Protein Synthesis Inhibitors/pharmacology | 5 | 1.0 |
Receptors, Cell Surface/immunology/*metabolism | 4 | 12.0 |
Antigens, Surface/immunology/metabolism | 2 | 14.0 |
Carrier Proteins/immunology/metabolism | 2 | 15.0 |
Escherichia coli | 20 | 4.0 |
Gene Expression/drug effects | 11 | 1.0 |
Lipid A/*immunology | 2 | 33.0 |
Membrane Glycoproteins/genetics/*immunology/metabolism | 2 | 28.0 |
Receptors, Cell Surface/genetics/*immunology/metabolism | 2 | 50.0 |
Sensitivity and Specificity | 22 | 0.0 |
HIV-1/*physiology | 3 | 0.0 |
Virus Replication | 8 | 0.0 |
Flow Cytometry/methods | 20 | 7.0 |
Immunohistochemistry/methods | 4 | 0.0 |
Immunophenotyping/methods | 3 | 6.0 |
Macrophages/chemistry/*pathology | 2 | 33.0 |
Antigens, CD/blood | 16 | 6.0 |
Biological Markers/blood | 11 | 0.0 |
Graft Rejection/*immunology | 4 | 5.0 |
Killer Cells, Natural/immunology | 4 | 0.0 |
Interferon-alpha/*therapeutic use | 2 | 3.0 |
Interleukin-6/metabolism | 10 | 4.0 |
Carbohydrate Conformation | 5 | 4.0 |
Carbohydrate Sequence | 7 | 2.0 |
Immunity, Natural/immunology | 2 | 8.0 |
Lipopolysaccharides/chemistry/*immunology | 2 | 40.0 |
Phagocytes/immunology | 4 | 16.0 |
Cell Communication/*immunology | 2 | 4.0 |
HLA-DR Antigens/analysis | 57 | 8.0 |
Intercellular Adhesion Molecule-1/analysis | 10 | 9.0 |
Lung/cytology | 3 | 5.0 |
HLA-D Antigens/analysis | 4 | 7.0 |
Inflammation Mediators/analysis | 2 | 8.0 |
Syndrome | 3 | 0.0 |
T-Lymphocytes/*immunology | 34 | 1.0 |
Antigens, CD18/*metabolism | 5 | 26.0 |
Interleukin-8/metabolism | 8 | 6.0 |
Lymphocyte Function-Associated Antigen-1/*metabolism | 2 | 7.0 |
Calcitriol/metabolism | 2 | 6.0 |
Culture Media/chemistry/pharmacology | 3 | 27.0 |
Forskolin/pharmacology | 5 | 1.0 |
Parathyroid Hormone/pharmacology | 2 | 7.0 |
Asthma/*genetics | 4 | 6.0 |
HLA-DR Antigens/genetics | 2 | 0.0 |
Mites/*immunology | 2 | 4.0 |
Receptors, IgE/analysis | 6 | 20.0 |
Antigens, Surface/analysis | 53 | 12.0 |
Cryopreservation | 3 | 2.0 |
Hydrocortisone/blood | 2 | 0.0 |
Immunity, Cellular/*physiology | 2 | 10.0 |
Killer Cells, Natural/*immunology | 5 | 1.0 |
Major Histocompatibility Complex/immunology | 2 | 4.0 |
Culture Media, Serum-Free | 19 | 4.0 |
Lipid A/pharmacology | 8 | 40.0 |
Macrophages/drug effects/*immunology/metabolism | 2 | 25.0 |
Tumor Necrosis Factor-alpha/genetics/*metabolism | 4 | 7.0 |
Antigens, Surface/biosynthesis | 8 | 13.0 |
Integrin alpha4 | 2 | 5.0 |
Integrin alphaXbeta2/biosynthesis | 5 | 62.0 |
Macrophages/*physiology | 8 | 8.0 |
Monocytes/*enzymology | 2 | 7.0 |
Receptors, IgG/biosynthesis | 12 | 42.0 |
Antigens, CD1/analysis | 9 | 11.0 |
Fetus | 4 | 0.0 |
Frozen Sections | 2 | 2.0 |
Immunoglobulins/analysis | 6 | 2.0 |
Receptors, Interleukin-3/analysis | 2 | 18.0 |
APACHE | 3 | 5.0 |
Cell Membrane/chemistry | 2 | 1.0 |
Comorbidity | 2 | 0.0 |
Inflammation | 11 | 2.0 |
Acid Phosphatase/metabolism | 4 | 6.0 |
Bone Resorption/*pathology | 2 | 50.0 |
Cell Differentiation/drug effects/*physiology | 5 | 7.0 |
Cytokines/*pharmacology | 11 | 2.0 |
Isoenzymes/metabolism | 3 | 0.0 |
Osteoclasts/*cytology/drug effects | 3 | 75.0 |
Synovial Fluid/cytology | 3 | 12.0 |
CD4 Lymphocyte Count | 3 | 0.0 |
Integrin alphaXbeta2/metabolism | 4 | 50.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Monocytes/*metabolism/microbiology | 3 | 75.0 |
Point Mutation | 5 | 0.0 |
Protein Kinases/metabolism | 2 | 0.0 |
Monocytes/drug effects/*immunology | 15 | 21.0 |
Depression, Chemical | 2 | 1.0 |
Guinea Pigs | 5 | 0.0 |
Macrophages/drug effects/metabolism | 3 | 7.0 |
Protein Binding/drug effects | 3 | 0.0 |
Shock, Septic/*prevention & control | 2 | 33.0 |
Tumor Necrosis Factor-alpha/*biosynthesis/genetics | 5 | 6.0 |
Administration, Inhalation | 4 | 2.0 |
Bronchoalveolar Lavage Fluid/cytology/immunology | 5 | 13.0 |
Macrophages, Alveolar/*drug effects | 2 | 50.0 |
Neutrophils/drug effects/*immunology | 4 | 13.0 |
Particle Size | 3 | 1.0 |
Antigens, CD14/blood/drug effects | 2 | 100.0 |
Interleukin-10/blood | 3 | 3.0 |
*Immunoconjugates | 4 | 1.0 |
Rhinitis, Allergic, Perennial/*immunology | 2 | 15.0 |
Membrane Glycoproteins/chemistry/genetics/*metabolism | 2 | 8.0 |
Mutagenesis | 3 | 0.0 |
Peptidoglycan/*metabolism | 7 | 63.0 |
Receptors, Cell Surface/chemistry/genetics/*metabolism | 2 | 8.0 |
Staphylococcus aureus/*metabolism | 2 | 8.0 |
Antigens, CD/analysis/drug effects | 2 | 40.0 |
Antigens, CD34 | 26 | 4.0 |
Blood | 12 | 6.0 |
Cell Culture Techniques/methods | 15 | 7.0 |
Dendritic Cells/*cytology/immunology | 10 | 23.0 |
Gene Expression Regulation/drug effects/immunology | 2 | 5.0 |
Hematopoietic Stem Cells/cytology/*drug effects | 4 | 7.0 |
Monocytes/cytology/*drug effects | 7 | 53.0 |
Haplotypes | 3 | 0.0 |
Lipopolysaccharides/*blood | 3 | 30.0 |
Cell Wall/immunology | 5 | 26.0 |
Membrane Glycoproteins/genetics/*immunology | 2 | 3.0 |
Receptors, Cell Surface/genetics/*immunology | 2 | 8.0 |
Antigens, CD80/analysis | 3 | 6.0 |
Interleukin-10/biosynthesis | 7 | 5.0 |
Transforming Growth Factor beta/biosynthesis | 3 | 6.0 |
Lymphocytes/immunology | 11 | 2.0 |
*Renal Dialysis | 10 | 2.0 |
Antigens, Differentiation, B-Lymphocyte/*analysis | 3 | 5.0 |
Antigens, Differentiation, T-Lymphocyte/*analysis | 5 | 2.0 |
Cell Cycle | 9 | 0.0 |
Cell Membrane Permeability | 3 | 1.0 |
DNA/analysis | 2 | 0.0 |
Formaldehyde/chemistry | 3 | 50.0 |
Immunophenotyping/*methods | 8 | 11.0 |
Polymers/chemistry | 2 | 8.0 |
Antigens, Surface/*blood | 3 | 20.0 |
Granulocytes/*metabolism | 2 | 5.0 |
Heart Defects, Congenital/surgery | 2 | 20.0 |
HLA-DR Antigens/*analysis | 13 | 7.0 |
Histocytochemistry | 17 | 2.0 |
Oxidation-Reduction | 4 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*administration & dosage | 2 | 11.0 |
Neoplasm Proteins/analysis | 3 | 0.0 |
Recombinant Proteins/administration & dosage | 3 | 3.0 |
Antigens, Differentiation/*analysis | 9 | 4.0 |
Gene Therapy | 2 | 0.0 |
Hematopoietic Stem Cells/immunology/*metabolism | 3 | 16.0 |
*Transfection | 2 | 0.0 |
Antigens, CD/genetics/*metabolism | 3 | 3.0 |
Antigens, CD14/genetics/*metabolism | 14 | 77.0 |
DNA Primers/genetics | 11 | 0.0 |
Immunoglobulin A/metabolism | 3 | 5.0 |
Intestinal Mucosa/*cytology/*immunology | 2 | 66.0 |
Macrophages/drug effects/*immunology | 5 | 26.0 |
Membrane Glycoproteins/genetics/metabolism | 3 | 3.0 |
Receptors, Cell Surface/genetics/metabolism | 3 | 4.0 |
Antineoplastic Agents/*pharmacology | 16 | 1.0 |
Antioxidants/*pharmacology | 2 | 1.0 |
Diterpenes/*pharmacology | 2 | 6.0 |
Gene Expression Regulation, Neoplastic/drug effects | 5 | 1.0 |
Granulocytes/*drug effects | 3 | 30.0 |
Monocytes/*drug effects | 9 | 16.0 |
Receptors, Calcitriol/analysis | 2 | 50.0 |
Retinoid X Receptors | 3 | 1.0 |
Transcription Factors/analysis | 2 | 2.0 |
Tretinoin/pharmacology | 17 | 5.0 |
Antineoplastic Combined Chemotherapy Protocols/administration & dosage | 2 | 6.0 |
Leukocytes, Mononuclear/metabolism | 20 | 9.0 |
Carrier Proteins/*physiology | 15 | 7.0 |
Membrane Glycoproteins/*physiology | 20 | 7.0 |
Receptors, Cell Surface/*physiology | 21 | 9.0 |
Antigens, Surface/*metabolism | 7 | 11.0 |
Glomerular Mesangium/metabolism/pathology | 2 | 33.0 |
Glomerulonephritis, IGA/*metabolism/pathology | 3 | 37.0 |
Leukocytes/pathology | 4 | 13.0 |
Cell Transformation, Neoplastic/*drug effects | 4 | 11.0 |
Leukemia, Monocytic, Acute/*pathology | 6 | 46.0 |
Retinoids/*pharmacology | 2 | 3.0 |
Tumor Stem Cells/*pathology | 2 | 7.0 |
Integrin alphaXbeta2/analysis | 2 | 13.0 |
L-Selectin/analysis | 2 | 10.0 |
Lymphocyte Function-Associated Antigen-1/analysis | 3 | 7.0 |
Antigens, CD/*classification | 2 | 66.0 |
ROC Curve | 2 | 1.0 |
Antigen-Presenting Cells | 3 | 15.0 |
Antigens, CD40 | 2 | 3.0 |
Antigens, Differentiation | 6 | 8.0 |
CD40 Ligand | 6 | 3.0 |
*Immunity, Cellular | 3 | 2.0 |
Biological Transport, Active | 4 | 2.0 |
Inflammation/blood/immunology | 3 | 42.0 |
Lipoproteins/*blood | 2 | 0.0 |
Monocytes/*drug effects/*immunology | 7 | 53.0 |
Receptors, IgG/blood | 6 | 42.0 |
Up-Regulation/drug effects | 14 | 3.0 |
Lipopolysaccharides | 9 | 7.0 |
Membrane Glycoproteins/genetics/immunology/*metabolism | 2 | 14.0 |
Antigens, Differentiation, Myelomonocytic/metabolism | 33 | 21.0 |
DNA-Binding Proteins/*genetics | 3 | 0.0 |
Transcription Factors/*genetics | 2 | 0.0 |
Enzyme Activation | 15 | 0.0 |
Membrane Glycoproteins/*biosynthesis | 4 | 4.0 |
Receptors, Cell Surface/*biosynthesis | 4 | 7.0 |
Antigens, CD3/biosynthesis | 3 | 5.0 |
*Down-Regulation | 6 | 1.0 |
Macrophages/*metabolism | 12 | 5.0 |
Membrane Proteins/*biosynthesis | 2 | 3.0 |
Mitogen-Activated Protein Kinases/*metabolism | 6 | 1.0 |
Neutrophils/*physiology | 7 | 4.0 |
Bone Marrow Cells | 23 | 5.0 |
Anticholesteremic Agents/*therapeutic use | 2 | 3.0 |
Cell Adhesion Molecules/*blood | 3 | 5.0 |
L-Selectin/blood | 2 | 22.0 |
Macrophage-1 Antigen/blood | 4 | 33.0 |
*Gene Expression Regulation, Enzymologic | 3 | 0.0 |
Macrophages/*enzymology | 3 | 9.0 |
Monocyte Chemoattractant Protein-1/genetics | 2 | 10.0 |
*Up-Regulation | 4 | 1.0 |
Anti-Inflammatory Agents, Non-Steroidal/*pharmacology | 3 | 2.0 |
Dendritic Cells/*drug effects | 2 | 18.0 |
Killer Cells, Natural/drug effects | 2 | 5.0 |
T-Lymphocytes/drug effects | 3 | 5.0 |
Nitric Oxide/metabolism | 5 | 2.0 |
Nuclear Proteins/metabolism | 3 | 0.0 |
Prostaglandin-Endoperoxide Synthase/metabolism | 2 | 2.0 |
Transcription Factors/metabolism | 3 | 0.0 |
Dendritic Cells/*cytology/*drug effects/immunology/metabolism | 2 | 100.0 |
Interferon Type II/metabolism | 4 | 1.0 |
Monocytes/*cytology/*drug effects/metabolism | 3 | 75.0 |
Antigens, CD3/immunology | 5 | 1.0 |
Apoptosis/drug effects/*physiology | 4 | 1.0 |
Monocytes/drug effects/*physiology | 4 | 10.0 |
Phytohemagglutinins/pharmacology | 5 | 0.0 |
Stem Cells/*physiology | 2 | 3.0 |
Adjuvants, Immunologic/*pharmacology | 8 | 4.0 |
Macrophages/drug effects/*metabolism | 5 | 8.0 |
Membrane Glycoproteins/physiology | 6 | 3.0 |
Glycoproteins/*metabolism | 2 | 1.0 |
Macrophages, Peritoneal/metabolism | 2 | 8.0 |
Membrane Glycoproteins/biosynthesis/*metabolism | 2 | 22.0 |
Monocytes/drug effects/immunology/metabolism | 5 | 26.0 |
Receptors, Cell Surface/biosynthesis/*metabolism | 2 | 15.0 |
Rabbits | 18 | 0.0 |
Antibody Specificity | 4 | 0.0 |
Antigens, CD | 13 | 9.0 |
Biopsy, Needle | 3 | 0.0 |
E-Selectin/analysis | 2 | 10.0 |
Interleukins/analysis | 4 | 12.0 |
Biocompatible Materials | 3 | 4.0 |
Blood Proteins/pharmacology | 4 | 9.0 |
Cell Death/drug effects | 3 | 1.0 |
Fibrosarcoma | 2 | 4.0 |
Fibrosis | 4 | 2.0 |
Glucuronic Acid | 3 | 15.0 |
Hexuronic Acids | 3 | 30.0 |
Jurkat Cells | 7 | 0.0 |
Lipid A/*analogs & derivatives/pharmacology | 4 | 21.0 |
Monocytes/cytology/drug effects/metabolism | 3 | 11.0 |
Necrosis | 2 | 0.0 |
Antigens, CD13/analysis | 5 | 20.0 |
Interleukin-1/secretion | 4 | 9.0 |
Interleukin-6/secretion | 6 | 10.0 |
Mice, Nude | 4 | 0.0 |
Neoplasm Transplantation | 3 | 0.0 |
Tumor Markers, Biological/analysis | 10 | 1.0 |
Vimentin/analysis | 6 | 2.0 |
Gelatinase B/metabolism | 2 | 3.0 |
Dose-Response Relationship, Immunologic | 21 | 4.0 |
Glycolipids/physiology | 2 | 33.0 |
Macrophages/immunology/metabolism | 6 | 13.0 |
NF-kappa B/physiology | 6 | 6.0 |
Receptors, Interleukin-2/biosynthesis | 4 | 3.0 |
Signal Transduction/genetics/immunology | 4 | 5.0 |
Arachidonic Acid/pharmacology | 3 | 7.0 |
Cell Survival/drug effects/physiology | 2 | 2.0 |
Interleukin-18/*metabolism | 2 | 40.0 |
Adenoviridae/genetics | 2 | 0.0 |
Cell Nucleus/metabolism | 9 | 0.0 |
Glutathione Transferase/metabolism | 3 | 0.0 |
Luciferases/metabolism | 3 | 0.0 |
Protein Isoforms | 2 | 0.0 |
*Reactive Oxygen Species | 2 | 7.0 |
Superoxides/metabolism | 19 | 7.0 |
Endocytosis/immunology | 5 | 22.0 |
Interleukin-8/biosynthesis/genetics | 2 | 8.0 |
Intracellular Fluid/immunology | 2 | 13.0 |
RNA, Messenger | 3 | 0.0 |
Antigens, CD34/analysis | 19 | 2.0 |
Blood Donors | 4 | 1.0 |
Sex Characteristics | 2 | 0.0 |
Receptors, IgE/*metabolism | 2 | 5.0 |
Antigens, Surface/*analysis | 20 | 10.0 |
Ionomycin/pharmacology | 6 | 2.0 |
Lymphocyte Activation/drug effects | 12 | 2.0 |
Leukocytes/*metabolism | 3 | 3.0 |
Protein Precursors/*pharmacology | 2 | 10.0 |
Cross Reactions/immunology | 2 | 4.0 |
*Cell Cycle Proteins | 4 | 0.0 |
Granulocytes/cytology/metabolism | 2 | 25.0 |
*Saccharomyces cerevisiae Proteins | 2 | 0.0 |
3T3 Cells | 4 | 0.0 |
Cell Survival/*drug effects | 2 | 2.0 |
Lymphocyte Activation/*drug effects | 5 | 1.0 |
Microscopy, Electron, Scanning | 6 | 2.0 |
Stress, Mechanical | 2 | 0.0 |
Antigens, CD56/analysis | 6 | 9.0 |
Leukemia, Myelocytic, Acute/*immunology | 5 | 14.0 |
Neoplasm, Residual/*diagnosis | 2 | 4.0 |
DNA/metabolism | 7 | 0.0 |
Intestines/*cytology | 2 | 12.0 |
*Antigen Presentation | 3 | 1.0 |
Antigens, CD80/metabolism | 3 | 3.0 |
Shock, Septic/drug therapy/immunology | 2 | 100.0 |
Alcohol Drinking | 3 | 2.0 |
Odds Ratio | 4 | 0.0 |
Promoter Regions (Genetics)/*genetics | 8 | 0.0 |
Peptide Fragments/*pharmacology | 3 | 1.0 |
Neoplasm Proteins/genetics | 2 | 0.0 |
P-Glycoprotein/genetics | 2 | 6.0 |
Receptors, Retinoic Acid/genetics | 4 | 4.0 |
Kidney Failure, Chronic/*blood/therapy | 2 | 3.0 |
Macrophage Colony-Stimulating Factor/blood | 2 | 28.0 |
Monocytes/*immunology/*pathology | 2 | 66.0 |
Peritoneal Dialysis, Continuous Ambulatory | 2 | 4.0 |
Blood Proteins/metabolism | 3 | 1.0 |
Macrophages/*immunology/metabolism | 5 | 21.0 |
Receptors, Immunologic/metabolism | 8 | 5.0 |
Cell Separation/*methods | 13 | 9.0 |
Leukocytes, Mononuclear/cytology/immunology | 2 | 4.0 |
Macaca mulatta | 3 | 0.0 |
Antigens, CD45/biosynthesis | 3 | 5.0 |
*Biocompatible Materials | 3 | 8.0 |
Lymphocytes/metabolism | 4 | 1.0 |
Macrophage-1 Antigen/biosynthesis | 7 | 25.0 |
*Membranes, Artificial | 6 | 7.0 |
Tetrazolium Salts/pharmacology | 2 | 3.0 |
Thiazoles/pharmacology | 2 | 1.0 |
Recombinant Fusion Proteins/metabolism | 4 | 0.0 |
Antigen Presentation/drug effects | 5 | 16.0 |
Antigens, CD58/biosynthesis | 2 | 28.0 |
Intercellular Adhesion Molecule-1/biosynthesis | 6 | 7.0 |
Monocytes/*drug effects/physiology | 7 | 33.0 |
Peptidoglycan/*pharmacology | 2 | 33.0 |
*Aftercare | 2 | 12.0 |
Attitude of Health Personnel | 2 | 6.0 |
Drug Utilization Review/*statistics & numerical data | 2 | 16.0 |
Emergency Treatment/*utilization | 2 | 20.0 |
England | 2 | 1.0 |
Family Practice | 2 | 6.0 |
Home Care Services | 2 | 13.0 |
House Calls/*utilization | 2 | 20.0 |
Patient Compliance | 2 | 1.0 |
Patient Education | 3 | 5.0 |
Patient Readmission/*statistics & numerical data | 2 | 18.0 |
Pharmacies | 2 | 20.0 |
*Pharmacists | 2 | 20.0 |
Quality of Life | 2 | 1.0 |
Self Administration/*statistics & numerical data | 2 | 20.0 |
United States | 3 | 0.0 |
Immunosuppressive Agents/*therapeutic use | 2 | 1.0 |
Gram-Negative Bacterial Infections/*complications/immunology | 2 | 100.0 |
Complement/immunology | 2 | 2.0 |
Interleukin-10/metabolism | 2 | 3.0 |
Interleukin-12/metabolism | 3 | 5.0 |
Interleukin-18/metabolism | 2 | 40.0 |
Cell Line, Tumor | 15 | 0.0 |
*Cytotoxicity, Immunologic | 2 | 0.0 |
Reactive Oxygen Species | 2 | 1.0 |
Adenosine Triphosphate/metabolism | 2 | 0.0 |
Antigens, CD14/genetics/*immunology | 6 | 85.0 |
Calcium/*metabolism | 2 | 0.0 |
Gene Transfer Techniques | 2 | 0.0 |
Ionophores/pharmacology | 6 | 4.0 |
Monocytes/drug effects/immunology/*metabolism | 3 | 23.0 |
Fluorescent Antibody Technique, Indirect | 9 | 1.0 |
Macrophages/metabolism/*pathology | 2 | 20.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
Receptors, CCR5/*biosynthesis | 2 | 8.0 |
Recombinant Proteins | 11 | 1.0 |
Antigens, CD11/analysis | 8 | 27.0 |
Dendritic Cells/cytology | 2 | 16.0 |
Leukocytes/*cytology | 4 | 21.0 |
Macrophages/*cytology | 14 | 43.0 |
Microscopy, Immunoelectron | 6 | 1.0 |
Rats | 24 | 0.0 |
Rats, Wistar | 4 | 0.0 |
Receptors, Antigen, T-Cell, gamma-delta/analysis | 2 | 5.0 |
T-Lymphocytes/cytology | 4 | 4.0 |
Biological Markers/*analysis | 3 | 2.0 |
Cell Culture Techniques/*methods | 8 | 8.0 |
Macrophages | 3 | 3.0 |
HL-60 Cells/drug effects | 5 | 22.0 |
*Tumor Suppressor Proteins | 3 | 0.0 |
Antigens, CD14/blood/*genetics | 2 | 100.0 |
Immunoglobulin E/*biosynthesis | 2 | 4.0 |
Escherichia coli/*metabolism | 2 | 7.0 |
Fimbriae, Bacterial/*metabolism | 2 | 28.0 |
Infant, Newborn/*immunology | 2 | 8.0 |
Infant, Premature/*immunology | 3 | 42.0 |
Antineoplastic Agents/therapeutic use | 4 | 1.0 |
*Proto-Oncogene Proteins | 3 | 0.0 |
Gene Expression Regulation, Leukemic/*drug effects | 4 | 11.0 |
Gene Therapy/*methods | 2 | 0.0 |
Macrophages/immunology/*virology | 2 | 15.0 |
Sequence Alignment | 5 | 0.0 |
Cytotoxicity, Immunologic/drug effects | 3 | 2.0 |
Models, Molecular | 2 | 0.0 |
Protein Conformation | 6 | 0.0 |
Sequence Homology, Amino Acid | 5 | 0.0 |
Lipoproteins/immunology | 2 | 18.0 |
Membrane Glycoproteins/deficiency/genetics/*immunology | 2 | 100.0 |
Receptors, Cell Surface/deficiency/genetics/*immunology | 2 | 100.0 |
Chromatography, Affinity | 5 | 0.0 |
Energy Transfer | 3 | 5.0 |
Lipopolysaccharides/metabolism/toxicity | 2 | 50.0 |
Peptide Mapping | 2 | 0.0 |
Receptor Aggregation | 3 | 3.0 |
Antigens, CD14/chemistry/*metabolism | 2 | 100.0 |
Cross-Linking Reagents | 5 | 1.0 |
Lipopolysaccharides/chemistry/*metabolism | 2 | 28.0 |
Recombinant Proteins/chemistry/metabolism | 2 | 0.0 |
Ultraviolet Rays | 3 | 0.0 |
Leukocyte Count/*methods | 3 | 37.0 |
Amyloidosis/etiology/*metabolism | 2 | 66.0 |
Chemotaxis, Leukocyte | 5 | 2.0 |
Collagen/metabolism | 2 | 0.0 |
Leukocytes, Mononuclear/*physiology | 3 | 12.0 |
Cystic Fibrosis/microbiology | 2 | 66.0 |
Macrophages/immunology/microbiology | 2 | 50.0 |
Monocytes/immunology/*microbiology | 3 | 25.0 |
Antigens, CD56/*biosynthesis | 2 | 22.0 |
Decidua/cytology/*immunology/*metabolism | 2 | 100.0 |
Binding Sites/genetics/immunology | 3 | 6.0 |
Gene Expression Regulation/immunology | 5 | 3.0 |
Intracellular Fluid/immunology/metabolism | 2 | 6.0 |
NF-kappa B/genetics/metabolism | 4 | 7.0 |
Signal Transduction/genetics/*immunology | 2 | 2.0 |
B-Lymphocytes/immunology | 12 | 1.0 |
Antigens, Differentiation/*physiology | 2 | 2.0 |
NF-kappa B/*physiology | 2 | 2.0 |
Protein Kinases/*physiology | 2 | 3.0 |
*Receptors, Immunologic | 2 | 1.0 |
Cell Wall/physiology | 2 | 66.0 |
Membrane Proteins/*physiology | 3 | 2.0 |
Interleukin-8/secretion | 8 | 20.0 |
Oxidative Stress | 2 | 0.0 |
*Immune Tolerance | 4 | 2.0 |
Membrane Glycoproteins/immunology/metabolism | 2 | 6.0 |
Monocytes/*drug effects/immunology | 7 | 17.0 |
Acylation | 6 | 8.0 |
Antigens, Bacterial/immunology | 7 | 6.0 |
Antigens, CD14/genetics/*immunology/metabolism | 3 | 100.0 |
Antigens, Viral/immunology | 2 | 1.0 |
Carrier Proteins/immunology/*metabolism | 2 | 10.0 |
Tumor Necrosis Factor-alpha/physiology | 5 | 3.0 |
Questionnaires | 2 | 0.0 |
Carcinogens/*pharmacology | 3 | 4.0 |
Tumor Necrosis Factor-alpha/analysis/metabolism | 2 | 11.0 |
Fluorescent Dyes/metabolism | 2 | 2.0 |
Granulocytes/metabolism | 2 | 5.0 |
Hematopoietic Stem Cells/*metabolism | 5 | 3.0 |
*Cell Differentiation/drug effects | 2 | 6.0 |
Dendritic Cells/*cytology/*immunology | 2 | 13.0 |
Membrane Glycoproteins/analysis/*biosynthesis | 2 | 16.0 |
Endopeptidase K/metabolism | 2 | 13.0 |
Membrane Proteins/metabolism | 7 | 1.0 |
Phosphatidylinositol Diacylglycerol-Lyase | 9 | 9.0 |
Phospholipase C/metabolism | 4 | 1.0 |
Antigens, CD36/analysis | 3 | 20.0 |
Leukocytes, Mononuclear/*immunology | 16 | 9.0 |
Lipids/blood | 5 | 0.0 |
Lipoproteins, HDL Cholesterol/blood | 2 | 0.0 |
Smoking | 3 | 0.0 |
Antigens, CD/biosynthesis/metabolism | 2 | 18.0 |
Antigens, Differentiation, Myelomonocytic/biosynthesis | 10 | 21.0 |
Lymphocytes/drug effects/*immunology | 2 | 4.0 |
Skin Tests | 3 | 1.0 |
*Biological Markers | 2 | 1.0 |
Granulocytes/cytology | 7 | 14.0 |
Killer Cells, Natural/cytology | 2 | 8.0 |
Macrophages/cytology | 6 | 8.0 |
MAP Kinase Signaling System | 3 | 1.0 |
Mitogen-Activated Protein Kinases/*physiology | 2 | 2.0 |
Inflammation/*genetics | 2 | 12.0 |
Tumor Necrosis Factor-alpha/genetics | 10 | 4.0 |
Cells, Cultured/drug effects | 3 | 3.0 |
Milk, Human/*chemistry | 2 | 4.0 |
Animals, Newborn | 3 | 0.0 |
Chemotaxis, Leukocyte/*physiology | 2 | 6.0 |
Glycoproteins/*physiology | 2 | 3.0 |
Pulmonary Surfactant-Associated Protein A | 5 | 16.0 |
Pulmonary Surfactant-Associated Proteins | 5 | 13.0 |
Sheep | 5 | 0.0 |
Monocytes/immunology/metabolism/pathology | 2 | 40.0 |
Hydrogen Peroxide/metabolism | 2 | 1.0 |
Kidney/*metabolism | 3 | 1.0 |
Carrier Proteins/genetics/*metabolism | 2 | 0.0 |
Glycoproteins/metabolism | 2 | 1.0 |
Cell Adhesion Molecules/*biosynthesis | 5 | 5.0 |
Cell Compartmentation | 3 | 0.0 |
E-Selectin/biosynthesis | 4 | 22.0 |
Endothelium, Vascular/*drug effects | 2 | 3.0 |
Lipopolysaccharides/immunology/*pharmacology | 2 | 50.0 |
Vascular Cell Adhesion Molecule-1/biosynthesis | 2 | 5.0 |
Bone Marrow/embryology | 2 | 8.0 |
Bone Marrow Cells/*metabolism | 5 | 10.0 |
DNA/chemistry | 3 | 1.0 |
G0 Phase | 2 | 2.0 |
G1 Phase | 3 | 0.0 |
Mice, SCID | 9 | 1.0 |
*Mutation | 3 | 0.0 |
S Phase | 2 | 0.0 |
Sequence Analysis, DNA | 3 | 0.0 |
Stem Cells/*cytology | 4 | 4.0 |
Extracellular Matrix/physiology | 3 | 3.0 |
Hematopoiesis/*physiology | 3 | 3.0 |
Integrins/physiology | 2 | 2.0 |
Flavonoids/pharmacology | 2 | 0.0 |
G1 Phase/drug effects | 2 | 1.0 |
Monocytes/cytology | 12 | 11.0 |
Bacterial Adhesion | 3 | 4.0 |
Molecular Weight | 18 | 0.0 |
Bacterial Proteins | 3 | 9.0 |
Cell Membrane Permeability/drug effects | 2 | 3.0 |
Streptococcus pneumoniae/*pathogenicity | 2 | 66.0 |
Antigens, CD/analysis/metabolism | 5 | 35.0 |
Eosinophil Granule Proteins | 4 | 1.0 |
HLA-DR Antigens/analysis/metabolism | 2 | 40.0 |
Immunoglobulin G/immunology | 7 | 2.0 |
Linear Models | 2 | 0.0 |
Respiratory Function Tests | 2 | 1.0 |
*Ribonucleases | 4 | 1.0 |
Chromatography, High Pressure Liquid | 5 | 0.0 |
Antigens, CD/*metabolism | 34 | 5.0 |
Antigens, Differentiation, Myelomonocytic/*metabolism | 25 | 43.0 |
Immunity, Cellular | 10 | 1.0 |
Leukemia/*immunology | 3 | 7.0 |
Life Style | 3 | 2.0 |
Antigens, CD4/biosynthesis | 3 | 3.0 |
Chromosome Banding | 7 | 0.0 |
Androstadienes/pharmacology | 3 | 1.0 |
Antigen-Presenting Cells/*immunology | 5 | 3.0 |
Antigens, CD/analysis/immunology | 5 | 10.0 |
HLA-DR Antigens/*analysis/immunology | 2 | 28.0 |
Microscopy, Electron/methods | 2 | 3.0 |
Staining and Labeling/methods | 3 | 2.0 |
Blood Proteins/analysis | 2 | 1.0 |
Lipopolysaccharides/*administration & dosage | 2 | 20.0 |
Neutrophils/drug effects/*physiology | 4 | 6.0 |
Cell Wall/*immunology | 2 | 40.0 |
In Situ Hybridization | 6 | 0.0 |
Interleukin-1/pharmacology | 15 | 2.0 |
RNA, Messenger/analysis/genetics | 4 | 0.0 |
Rats, Sprague-Dawley | 7 | 0.0 |
Antigens, CD14/genetics/metabolism/*physiology | 3 | 100.0 |
Phosphatidylserines/metabolism | 3 | 5.0 |
Phospholipids/*metabolism | 3 | 2.0 |
Cell Movement/drug effects/immunology | 2 | 14.0 |
Monocyte Chemoattractant Protein-1/pharmacology | 4 | 19.0 |
Monocytes/cytology/*immunology/*metabolism | 2 | 50.0 |
Tumor Necrosis Factor-alpha/genetics/immunology/metabolism | 2 | 66.0 |
Up-Regulation/immunology | 6 | 3.0 |
*Lymphocyte Activation | 17 | 1.0 |
Chromosomes, Human, Pair 8/*genetics | 3 | 2.0 |
Skin/*pathology | 3 | 3.0 |
Monocytes/drug effects/immunology | 6 | 15.0 |
Polysaccharides, Bacterial/*immunology | 3 | 12.0 |
Cycloheximide/pharmacology | 13 | 1.0 |
Endothelium, Vascular/cytology/*metabolism | 3 | 1.0 |
Cytokines/physiology | 7 | 3.0 |
Hybridomas | 2 | 1.0 |
Receptors, IgG/analysis | 17 | 26.0 |
Antigens, CD36/blood | 2 | 40.0 |
Asthma/*immunology/therapy | 2 | 28.0 |
Endotoxins/*pharmacology | 10 | 12.0 |
Cell Adhesion Molecules/immunology | 5 | 7.0 |
Granulocytes/immunology | 10 | 17.0 |
Polymers | 3 | 2.0 |
Reactive Oxygen Species/immunology | 3 | 100.0 |
Histocompatibility Antigens Class II/*immunology | 2 | 1.0 |
Antibodies/metabolism | 2 | 2.0 |
Cholecalciferol/pharmacology | 7 | 21.0 |
Immunotherapy/methods | 3 | 3.0 |
Inflammation/etiology | 4 | 10.0 |
Biotinylation | 3 | 2.0 |
*Endocytosis | 2 | 1.0 |
Monocytes/cytology/immunology/*metabolism | 3 | 33.0 |
E-Selectin/*biosynthesis | 2 | 20.0 |
Endothelium, Vascular/cytology/metabolism | 2 | 1.0 |
Intercellular Adhesion Molecule-1/*biosynthesis | 6 | 13.0 |
Anti-Inflammatory Agents/*pharmacology | 2 | 2.0 |
Dexamethasone/*pharmacology | 4 | 1.0 |
HLA-DR Antigens/blood | 4 | 7.0 |
Immunization, Passive | 2 | 2.0 |
Antigens, Surface/immunology | 8 | 4.0 |
Autoantigens/immunology | 2 | 1.0 |
Bone Marrow/*immunology/metabolism | 3 | 60.0 |
Cytotoxicity, Immunologic | 11 | 1.0 |
Kidney Neoplasms/*immunology/pathology | 2 | 16.0 |
Lymphocyte Activation/*immunology | 7 | 1.0 |
T-Lymphocyte Subsets/immunology | 6 | 1.0 |
Antigens, CD55/analysis | 2 | 10.0 |
Antigens, CD59/analysis | 2 | 9.0 |
Erythrocytes/immunology | 6 | 2.0 |
Evaluation Studies | 5 | 0.0 |
*Flow Cytometry | 18 | 10.0 |
Hemoglobinuria, Paroxysmal/*blood | 4 | 15.0 |
Fixatives | 3 | 4.0 |
Formaldehyde | 3 | 3.0 |
Hydrolysis | 2 | 0.0 |
Polymorphism, Genetic/*genetics | 2 | 0.0 |
Astrocytoma | 4 | 11.0 |
Antigens, CD8/blood | 2 | 5.0 |
Macaca mulatta/*immunology | 2 | 14.0 |
Antigens, CD34/*metabolism | 4 | 3.0 |
Bone Marrow Cells/cytology/metabolism | 2 | 10.0 |
Cell Separation/methods | 11 | 7.0 |
Dimethyl Sulfoxide/pharmacology | 2 | 2.0 |
Enzyme Induction/drug effects | 3 | 0.0 |
Cyclic AMP-Dependent Protein Kinases/metabolism | 2 | 1.0 |
Leukemia, Myelocytic, Acute | 2 | 7.0 |
Retinoblastoma Protein/*metabolism | 2 | 1.0 |
DNA Probes | 3 | 0.0 |
Biological Transport/immunology | 3 | 11.0 |
Cell Adhesion/immunology | 10 | 5.0 |
Spectrometry, Fluorescence | 3 | 0.0 |
Bronchoalveolar Lavage Fluid/*cytology | 3 | 6.0 |
Lymphocyte Count | 9 | 1.0 |
Annexin A5/analysis | 3 | 13.0 |
Blood Cell Count | 5 | 2.0 |
Centrifugation, Density Gradient | 9 | 2.0 |
Cryopreservation/*methods | 3 | 17.0 |
Antibodies/*immunology | 2 | 1.0 |
Decidua/immunology | 2 | 25.0 |
Fibroblasts/immunology | 2 | 2.0 |
Keratin/analysis | 6 | 2.0 |
Placenta/*immunology | 2 | 9.0 |
Leukemia, Myeloid/*pathology | 7 | 13.0 |
Myelodysplastic Syndromes/*pathology | 3 | 10.0 |
Antigens, Differentiation, Myelomonocytic/*biosynthesis | 9 | 60.0 |
Dendritic Cells/metabolism | 2 | 4.0 |
Dexamethasone/pharmacology | 11 | 2.0 |
Glucocorticoids/pharmacology | 3 | 2.0 |
Interleukin-13/pharmacology | 3 | 7.0 |
*Receptors, Cell Surface | 8 | 2.0 |
Antigens, CD56/metabolism | 2 | 7.0 |
Antigens, CD11/immunology | 3 | 27.0 |
Antigens, CD4/immunology | 2 | 1.0 |
Bone Marrow/pathology | 17 | 4.0 |
Chromosome Aberrations | 10 | 1.0 |
Chromosome Disorders | 8 | 2.0 |
Leukemia, Myeloid/diagnosis/*immunology | 2 | 66.0 |
Interleukin-10/genetics | 2 | 4.0 |
Dendritic Cells/cytology/drug effects/*immunology | 3 | 13.0 |
T-Lymphocytes/drug effects/*immunology | 2 | 1.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 16 | 1.0 |
Immunoglobulin G/pharmacology | 3 | 5.0 |
Peroxidase/immunology | 2 | 5.0 |
Deoxyribonuclease I/metabolism | 2 | 1.0 |
Liver/metabolism | 3 | 0.0 |
Mice, Transgenic | 4 | 0.0 |
Organ Specificity | 6 | 0.0 |
Staining and Labeling | 15 | 2.0 |
Hematopoiesis | 9 | 3.0 |
Immunoglobulins/biosynthesis | 5 | 4.0 |
L-Selectin/biosynthesis | 4 | 21.0 |
C-Reactive Protein/metabolism | 8 | 2.0 |
Graft Survival/immunology | 2 | 3.0 |
Monocytes/*drug effects/immunology/metabolism | 4 | 40.0 |
Cell Survival/drug effects/immunology | 3 | 16.0 |
*Drug Resistance, Neoplasm | 2 | 1.0 |
Gene Expression Regulation, Leukemic/drug effects | 2 | 8.0 |
Receptors, Tumor Necrosis Factor, Type I | 3 | 0.0 |
Tumor Necrosis Factor-alpha/*antagonists & inhibitors/physiology | 2 | 11.0 |
Cell Wall/metabolism | 2 | 14.0 |
Teichoic Acids/*metabolism | 2 | 16.0 |
Dendritic Cells/cytology/*immunology | 8 | 13.0 |
Hematopoietic Stem Cells/cytology/immunology | 3 | 9.0 |
Antigens, CD59/blood | 3 | 37.0 |
Blood Proteins/*metabolism | 5 | 2.0 |
Glycosylphosphatidylinositols/*blood | 2 | 28.0 |
Hemoglobinuria, Paroxysmal/*blood/*immunology | 2 | 66.0 |
Membrane Glycoproteins/blood | 3 | 10.0 |
*HIV-1 | 3 | 0.0 |
Antigens, Differentiation/metabolism | 7 | 5.0 |
Monocytes/*cytology/drug effects/metabolism | 4 | 66.0 |
Neovascularization, Physiologic | 2 | 1.0 |
Cell Adhesion/drug effects/immunology | 4 | 20.0 |
*Pertussis Toxin | 2 | 6.0 |
Antigens, CD18/metabolism | 9 | 20.0 |
Antigens, CD29/metabolism | 4 | 7.0 |
Monocytes/cytology/immunology | 4 | 11.0 |
Culicidae | 2 | 50.0 |
Tumor Necrosis Factor-alpha/*metabolism/pharmacology | 3 | 6.0 |
*Chromosome Mapping | 4 | 0.0 |
Chromosomes, Human, Pair 11 | 3 | 0.0 |
Chromosomes, Human, Pair 16 | 2 | 1.0 |
Chromosomes, Human, Pair 5 | 3 | 2.0 |
Antigens, CD11/biosynthesis | 2 | 22.0 |
Blood Proteins/*pharmacology | 2 | 5.0 |
Carrier Proteins/blood | 2 | 1.0 |
Leukocytes/*drug effects/*physiology | 2 | 40.0 |
CCAAT-Enhancer-Binding Proteins | 3 | 1.0 |
Electrophoresis | 2 | 0.0 |
Nuclear Proteins/*metabolism | 4 | 0.0 |
Synovial Membrane/*metabolism/pathology | 2 | 9.0 |
Antigens, CD18/biosynthesis | 3 | 33.0 |
Immunosuppressive Agents/pharmacology | 7 | 4.0 |
Monocytes/drug effects/*metabolism | 14 | 11.0 |
Bone Marrow Cells/cytology | 3 | 3.0 |
DNA Replication | 2 | 0.0 |
DNA, Viral/analysis | 3 | 0.0 |
Antigens, Differentiation, Myelomonocytic/*analysis | 35 | 34.0 |
Cytogenetics | 2 | 2.0 |
*Signal Transduction/drug effects | 2 | 2.0 |
Cell Adhesion Molecules/*immunology | 3 | 5.0 |
Cell Lineage/*immunology | 3 | 27.0 |
Leukocytes, Mononuclear/*cytology/*immunology | 2 | 66.0 |
Antigens, CD/*immunology | 19 | 4.0 |
Monocytes/*cytology/immunology | 7 | 36.0 |
Leukocytes/*immunology | 14 | 10.0 |
Receptors, IgG/*immunology | 3 | 9.0 |
Peroxidase/*metabolism | 2 | 3.0 |
Fluorescent Antibody Technique, Direct | 6 | 5.0 |
Hemolysis | 4 | 1.0 |
Antibodies, Monoclonal/immunology/pharmacology | 3 | 3.0 |
Macrophages/cytology/drug effects/metabolism | 2 | 11.0 |
Up-Regulation/*drug effects | 4 | 5.0 |
Annexin A5/pharmacology | 2 | 5.0 |
Antigens, CD13/biosynthesis | 2 | 28.0 |
Granulocyte Colony-Stimulating Factor/metabolism | 2 | 13.0 |
Leukemia, Myeloid/*metabolism | 2 | 6.0 |
Antigens, CD18/*immunology | 2 | 40.0 |
Granulocytes/*immunology | 2 | 5.0 |
HLA-DR Antigens/*immunology | 5 | 3.0 |
Fluorescence Resonance Energy Transfer | 2 | 4.0 |
G(M1) Ganglioside/metabolism | 2 | 10.0 |
Golgi Apparatus/*metabolism | 2 | 2.0 |
Plasmids/metabolism | 2 | 0.0 |
Staphylococcus aureus/metabolism | 3 | 16.0 |
Binding Sites, Antibody/drug effects | 2 | 16.0 |
Binding, Competitive/immunology | 3 | 3.0 |
Blood/immunology | 2 | 15.0 |
Dipeptides/pharmacology | 2 | 4.0 |
Formaldehyde/pharmacology | 4 | 14.0 |
Polymers/pharmacology | 2 | 9.0 |
Tumor Necrosis Factor-alpha/antagonists & inhibitors/biosynthesis | 4 | 18.0 |
Liver/cytology/*metabolism | 2 | 2.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Transcription Factor, Sp1/*physiology | 2 | 2.0 |
CD8-Positive T-Lymphocytes/immunology | 4 | 0.0 |
Cyclosporine/pharmacology | 4 | 1.0 |
Dendritic Cells/drug effects/*immunology | 5 | 19.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*pharmacology | 23 | 14.0 |
Interleukin-2/*pharmacology | 4 | 1.0 |
Pinocytosis/drug effects | 2 | 33.0 |
Leukocytes, Mononuclear/*drug effects/metabolism | 3 | 10.0 |
Nitric Oxide/*pharmacology | 2 | 4.0 |
Arthritis/*immunology | 2 | 8.0 |
Synovial Fluid/*immunology | 4 | 7.0 |
CD4-Positive T-Lymphocytes/immunology | 11 | 1.0 |
Alkaline Phosphatase/analysis | 3 | 5.0 |
Antigen Presentation/*immunology | 5 | 5.0 |
Antigens, CD45/immunology | 2 | 3.0 |
Intercellular Adhesion Molecule-1/immunology | 3 | 7.0 |
Osteoblasts/*immunology | 2 | 66.0 |
Calcium Channel Agonists/pharmacology | 2 | 9.0 |
Drug Stability | 3 | 1.0 |
Radioligand Assay | 3 | 0.0 |
Trans-Activators/metabolism | 2 | 0.0 |
Antigens, CD34/blood | 2 | 3.0 |
Hematopoietic Stem Cells/*cytology | 10 | 4.0 |
Mesoderm/*cytology | 2 | 7.0 |
Placenta/*cytology | 2 | 11.0 |
Adjuvants, Immunologic/pharmacology | 2 | 2.0 |
Immune Tolerance/drug effects | 3 | 11.0 |
T-Lymphocytes/drug effects/immunology | 4 | 4.0 |
Vitamin D/*analogs & derivatives/pharmacology | 2 | 28.0 |
Dendritic Cells/*cytology/drug effects/*immunology | 4 | 40.0 |
Estrogen Receptor alpha | 2 | 0.0 |
Estrogen Receptor beta | 2 | 2.0 |
Monocytes/cytology/*immunology | 9 | 25.0 |
Blood Cells/immunology | 2 | 6.0 |
Tumor Necrosis Factor-alpha/*genetics | 2 | 0.0 |
DNA/blood | 2 | 1.0 |
Monocytes/cytology/drug effects/*physiology | 3 | 42.0 |
Macrophages/*microbiology | 3 | 10.0 |
Monocytes/*microbiology | 4 | 14.0 |
*Mycobacterium tuberculosis | 2 | 16.0 |
Bacterial Proteins/metabolism | 2 | 3.0 |
Cell Membrane/immunology | 11 | 4.0 |
Receptors, Cell Surface/immunology | 4 | 11.0 |
Shock, Septic/immunology | 2 | 20.0 |
Antigens, CD14/analysis/immunology | 2 | 66.0 |
Antigens, Differentiation, Myelomonocytic/analysis/immunology | 2 | 12.0 |
HLA-DR Antigens/analysis/immunology | 2 | 10.0 |
Reagent Kits, Diagnostic | 2 | 1.0 |
Cell Size/drug effects | 2 | 2.0 |
Culture Media, Conditioned/pharmacology | 4 | 2.0 |
DNA/biosynthesis | 5 | 0.0 |
Hemoglobins/biosynthesis | 3 | 18.0 |
Protein Biosynthesis | 4 | 0.0 |
Dendritic Cells/immunology/*ultrastructure | 2 | 100.0 |
Interleukin-10/*secretion | 3 | 27.0 |
Fetal Blood/cytology/*immunology | 3 | 15.0 |
*Hematopoiesis | 3 | 1.0 |
Hematopoietic Stem Cells/*pathology | 3 | 4.0 |
Antigens, CD/*immunology/metabolism | 3 | 9.0 |
Receptors, Fc/*metabolism | 2 | 5.0 |
Antigens, CD14/biosynthesis/*genetics | 2 | 100.0 |
*Escherichia coli | 4 | 11.0 |
Immunoglobulin M/biosynthesis | 6 | 6.0 |
Interleukin-6/biosynthesis/genetics | 2 | 5.0 |
RNA, Messenger/*biosynthesis | 3 | 1.0 |
Drug Combinations | 5 | 0.0 |
Histocompatibility Antigens Class I/biosynthesis | 4 | 8.0 |
Antigens, CD13/metabolism | 3 | 33.0 |
CD4-Positive T-Lymphocytes | 2 | 0.0 |
HIV-1/*immunology | 3 | 0.0 |
Immunoglobulins/metabolism | 2 | 1.0 |
Phagocytes | 3 | 37.0 |
Intercellular Adhesion Molecule-1/*blood | 2 | 3.0 |
Leukocytes/immunology/*metabolism | 2 | 50.0 |
Dinoprostone/biosynthesis/pharmacology | 2 | 40.0 |
Growth Substances/pharmacology | 5 | 2.0 |
Bone Marrow Cells/*immunology | 2 | 7.0 |
Hematopoietic Stem Cells/*immunology | 7 | 4.0 |
Binding Sites, Antibody | 3 | 0.0 |
Epitope Mapping | 2 | 0.0 |
Lipopolysaccharides/antagonists & inhibitors/*metabolism | 4 | 50.0 |
Porphyromonas gingivalis/metabolism | 3 | 75.0 |
Protein Binding/genetics/immunology | 2 | 2.0 |
Dendritic Cells/pathology | 2 | 8.0 |
Langerhans Cells/*pathology | 2 | 15.0 |
Skin Diseases/immunology/*pathology | 2 | 50.0 |
Biopsy | 23 | 1.0 |
Diagnosis, Differential | 14 | 0.0 |
Leukocyte L1 Antigen Complex | 2 | 3.0 |
Macrophages/pathology | 2 | 1.0 |
Membrane Glycoproteins/*analysis | 5 | 3.0 |
T-Lymphocytes/pathology | 5 | 4.0 |
Antigens, CD11/blood | 3 | 42.0 |
Granulocytes/chemistry | 2 | 16.0 |
Lymphocytes/chemistry | 3 | 5.0 |
Monocytes/chemistry | 6 | 24.0 |
Bacterial Outer Membrane Proteins/immunology | 2 | 10.0 |
Blood/*immunology | 2 | 15.0 |
Carrier Proteins/physiology | 7 | 5.0 |
Lipid A/analogs & derivatives/immunology | 2 | 66.0 |
Lipopolysaccharides/*immunology/metabolism | 5 | 100.0 |
Neutrophil Activation/*immunology | 3 | 20.0 |
T-Lymphocytes/*cytology/*immunology | 2 | 11.0 |
Cell Cycle/*physiology | 2 | 0.0 |
Cell Death | 2 | 0.0 |
Monocytes/cytology/*physiology | 2 | 15.0 |
Plasmids | 2 | 0.0 |
*Proto-Oncogenes | 6 | 0.0 |
*Transcription Factors | 5 | 0.0 |
Blood Coagulation | 3 | 1.0 |
Lymphocyte Function-Associated Antigen-1/metabolism | 4 | 8.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
Macrophages/cytology/drug effects/physiology | 2 | 40.0 |
Plasmids/genetics | 3 | 0.0 |
Antigens, Differentiation/immunology | 3 | 2.0 |
Arthritis, Rheumatoid/*immunology/*pathology | 2 | 28.0 |
Multiple Myeloma/*pathology | 2 | 3.0 |
Tumor Necrosis Factor-alpha/*immunology | 3 | 2.0 |
Membrane Potentials/drug effects | 3 | 2.0 |
Carcinoma, Squamous Cell/metabolism/pathology | 2 | 5.0 |
Muromonab-CD3/pharmacology | 2 | 2.0 |
Fibroblasts/cytology | 2 | 0.0 |
Stem Cells/cytology | 4 | 5.0 |
Neprilysin/analysis | 2 | 3.0 |
Pregnancy Trimester, First | 2 | 0.0 |
Stromal Cells/immunology | 2 | 8.0 |
Antibodies, Monoclonal/biosynthesis | 2 | 7.0 |
Antigen-Antibody Reactions | 4 | 1.0 |
Epitopes/immunology | 3 | 0.0 |
Heat | 4 | 0.0 |
Lipopolysaccharides/antagonists & inhibitors/*immunology | 2 | 66.0 |
Membrane Glycoproteins/immunology/*physiology | 2 | 11.0 |
Monocytes/*immunology/*microbiology | 2 | 40.0 |
Receptors, Cell Surface/immunology/*physiology | 2 | 13.0 |
Streptococcus agalactiae/*immunology | 2 | 18.0 |
Cholesterol Esters/metabolism | 2 | 1.0 |
Cytological Techniques | 2 | 5.0 |
Immunotherapy, Adoptive | 2 | 2.0 |
Ovarian Neoplasms/*immunology | 3 | 9.0 |
Phosphatidylinositols/*metabolism | 4 | 4.0 |
Shock, Septic/*immunology | 3 | 21.0 |
Cadherins/analysis | 2 | 6.0 |
Epithelium/pathology | 2 | 1.0 |
Fibroblasts/pathology | 2 | 2.0 |
Peritoneum/*pathology | 2 | 16.0 |
Receptors, Tumor Necrosis Factor/*physiology | 2 | 2.0 |
Teichoic Acids/pharmacology | 3 | 23.0 |
Restriction Mapping | 3 | 0.0 |
Chromosomes, Human, Pair 21 | 4 | 3.0 |
Chromosomes, Human, Pair 8 | 3 | 2.0 |
Japan | 3 | 0.0 |
Translocation, Genetic | 5 | 0.0 |
Carrier Proteins/*pharmacology | 4 | 8.0 |
Membrane Glycoproteins/*pharmacology | 3 | 3.0 |
Antigens, Surface/*biosynthesis | 5 | 20.0 |
Cell Division/immunology | 6 | 2.0 |
Lymphocyte Subsets/drug effects | 3 | 15.0 |
T-Lymphocytes/cytology/drug effects/metabolism | 2 | 18.0 |
Dinoprostone/pharmacology | 5 | 6.0 |
Growth Inhibitors/*pharmacology | 2 | 1.0 |
Immunosuppressive Agents/*pharmacology | 6 | 2.0 |
NF-kappa B/biosynthesis/metabolism | 2 | 50.0 |
HIV-1/*growth & development | 6 | 9.0 |
Lipoproteins/*pharmacology | 3 | 6.0 |
*Antigens, Differentiation | 4 | 4.0 |
Apoptosis/*physiology | 3 | 0.0 |
Cell Adhesion Molecules/physiology | 6 | 6.0 |
Cell Membrane/metabolism/ultrastructure | 2 | 3.0 |
Gram-Positive Bacteria/*immunology/metabolism | 2 | 100.0 |
Lipid A/chemistry | 5 | 83.0 |
Lipopolysaccharides/chemistry/*immunology/metabolism | 2 | 66.0 |
Peptidoglycan/chemistry/*immunology/metabolism | 3 | 100.0 |
Cricetulus | 6 | 1.0 |
DNA, Complementary/genetics | 7 | 0.0 |
Gram-Negative Bacteria/*immunology | 5 | 38.0 |
Molecular Conformation | 2 | 0.0 |
Chromosomes, Human, Pair 5/genetics | 2 | 2.0 |
Gram-Negative Bacteria/immunology | 3 | 23.0 |
Neutrophils/physiology | 6 | 5.0 |
Antigens, CD14/metabolism/*physiology | 4 | 80.0 |
Macrophage Activation/*immunology | 8 | 27.0 |
Monocytes/*drug effects/metabolism | 11 | 11.0 |
Thromboplastin/*biosynthesis | 3 | 4.0 |
Cell Communication/immunology | 8 | 10.0 |
Mitogens/pharmacology | 4 | 1.0 |
Allergens/administration & dosage/*immunology | 2 | 28.0 |
Asthma/*immunology/pathology | 2 | 15.0 |
Bronchial Provocation Tests | 2 | 2.0 |
Bronchoalveolar Lavage Fluid/*cytology/immunology | 3 | 33.0 |
Forced Expiratory Volume | 2 | 2.0 |
Cell Nucleus/drug effects/metabolism | 3 | 5.0 |
Tumor Necrosis Factor-alpha/*secretion | 10 | 10.0 |
Lipopolysaccharides/*metabolism/pharmacology | 11 | 61.0 |
NF-kappa B/genetics | 3 | 8.0 |
Receptors, Cell Surface/biosynthesis/deficiency/genetics/*physiology | 2 | 50.0 |
Trans-Activation (Genetics)/immunology | 2 | 8.0 |
Chemokines, CC/metabolism/pharmacology | 2 | 12.0 |
Interleukin-4/*metabolism/pharmacology | 2 | 33.0 |
Recombinant Proteins/metabolism/pharmacology | 2 | 1.0 |
Automation | 2 | 3.0 |
Electrophoresis, Gel, Two-Dimensional | 4 | 1.0 |
Chromosome Mapping | 8 | 0.0 |
*Chromosomes, Human, Pair 5 | 6 | 2.0 |
*Genes, Tumor Suppressor | 2 | 0.0 |
Histone Deacetylases/*genetics | 2 | 11.0 |
Corneal Transplantation/*immunology | 2 | 16.0 |
Dendritic Cells/immunology | 4 | 2.0 |
HLA-DP Antigens/analysis | 2 | 14.0 |
Acetylgalactosamine/metabolism | 2 | 25.0 |
Carbohydrates/*metabolism | 3 | 7.0 |
Glomerulonephritis, IGA/*etiology | 2 | 66.0 |
Purpura, Schoenlein-Henoch/*etiology | 2 | 50.0 |
Factor VII/*antagonists & inhibitors/metabolism | 2 | 50.0 |
Haplorhini | 3 | 1.0 |
Thromboplastin/*antagonists & inhibitors | 2 | 9.0 |
p-Methoxy-N-methylphenethylamine/*pharmacology | 2 | 40.0 |
Antigens/immunology | 3 | 2.0 |
Interleukin-13/*pharmacology | 8 | 17.0 |
Leukocytes, Mononuclear/cytology | 5 | 10.0 |
HLA-DR Antigens | 4 | 1.0 |
Peritoneal Cavity/cytology | 3 | 7.0 |
Antigens, CD14 | 246 | 83.0 |
Macrophages/cytology/immunology | 2 | 10.0 |
Adjuvants, Immunologic/physiology | 3 | 6.0 |
Antibodies, Monoclonal/*pharmacology | 4 | 2.0 |
Down-Regulation/immunology | 6 | 6.0 |
Interleukin-4/*physiology | 2 | 4.0 |
Tumor Necrosis Factor-alpha/*physiology | 3 | 1.0 |
Antibodies, Blocking/pharmacology | 5 | 5.0 |
Antigens, CD40/*metabolism | 3 | 6.0 |
Apoptosis/*immunology | 5 | 2.0 |
Histocompatibility Antigens Class I/analysis | 4 | 4.0 |
Reference Standards | 4 | 1.0 |
Transforming Growth Factor beta/*pharmacology | 3 | 0.0 |
Granulocyte Colony-Stimulating Factor/*therapeutic use | 3 | 5.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*therapeutic use | 3 | 11.0 |
Transplantation, Autologous | 5 | 1.0 |
Antigens, CD/*biosynthesis/genetics | 3 | 5.0 |
Antigens, CD/*biosynthesis | 18 | 9.0 |
Antigens, CD80/*biosynthesis | 2 | 5.0 |
Inflammatory Bowel Diseases/*immunology | 2 | 8.0 |
Intestinal Mucosa/*immunology | 2 | 2.0 |
Macrophages/cytology/*immunology | 4 | 22.0 |
Th1 Cells/immunology | 4 | 2.0 |
B-Lymphocytes/cytology | 2 | 2.0 |
Escherichia coli/*physiology | 2 | 22.0 |
Immunoglobulin E/*blood | 4 | 7.0 |
Linkage (Genetics) | 5 | 0.0 |
Proteins/metabolism | 3 | 0.0 |
Hematopoietic Stem Cell Mobilization/methods | 2 | 11.0 |
Acute-Phase Proteins/metabolism | 3 | 4.0 |
Interleukin-2/metabolism | 3 | 2.0 |
Gene Expression Regulation, Bacterial | 3 | 5.0 |
Monocytes/cytology/drug effects | 7 | 20.0 |
Antigens, CD95/analysis | 2 | 6.0 |
Chromosomes, Human, Pair 22 | 2 | 1.0 |
Chromosomes, Human, Pair 9 | 3 | 1.0 |
Fusion Proteins, bcr-abl/*genetics | 2 | 2.0 |
Genes, MDR | 2 | 6.0 |
Umbilical Veins/cytology | 3 | 1.0 |
Culture Techniques | 2 | 0.0 |
Stimulation, Chemical | 7 | 1.0 |
Circular Dichroism | 2 | 0.0 |
HL-60 Cells/*drug effects | 2 | 40.0 |
Leukemia, Promyelocytic, Acute/drug therapy | 2 | 50.0 |
Leukocytes/*cytology/drug effects | 2 | 100.0 |
Neutrophils/cytology | 5 | 11.0 |
Epithelial Cells/immunology | 3 | 8.0 |
Metabolic Clearance Rate | 2 | 0.0 |
Colony-Stimulating Factors/pharmacology | 2 | 4.0 |
Interleukin-3/pharmacology | 6 | 2.0 |
Antigens, Differentiation, Myelomonocytic/blood | 5 | 31.0 |
Blood Coagulation Factors/*metabolism | 2 | 2.0 |
Interleukin-2/genetics/metabolism | 2 | 13.0 |
Peptide Fragments/metabolism | 4 | 1.0 |
N-Formylmethionine Leucyl-Phenylalanine/pharmacology | 25 | 9.0 |
*Neutrophil Activation | 3 | 9.0 |
Histocompatibility Testing | 4 | 0.0 |
Phagocytosis/*immunology | 6 | 10.0 |
Proteins/genetics/*metabolism | 2 | 0.0 |
Leukemia, Myelocytic, Acute/immunology/*pathology | 2 | 15.0 |
Borrelia burgdorferi Group/*immunology | 4 | 40.0 |
Boron Compounds | 2 | 25.0 |
Chimeric Proteins/metabolism | 3 | 1.0 |
Glycosylphosphatidylinositols | 7 | 13.0 |
Green Fluorescent Proteins | 3 | 0.0 |
Membrane Proteins/*metabolism | 8 | 1.0 |
Antigens, CD14/genetics/immunology | 2 | 66.0 |
Salmonella | 11 | 45.0 |
Fibroblasts/*immunology | 4 | 22.0 |
Porphyromonas gingivalis/*immunology | 3 | 14.0 |
Antigens, CD14/biosynthesis/genetics/*physiology | 2 | 100.0 |
Macrophage Activation/drug effects | 10 | 19.0 |
HLA-DR Antigens/immunology | 14 | 6.0 |
Immunotherapy, Adoptive/methods | 2 | 16.0 |
Th2 Cells/*immunology | 3 | 2.0 |
Combined Modality Therapy | 4 | 0.0 |
Antigens, CD14/immunology/*physiology | 8 | 88.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/immunology/pharmacology | 2 | 25.0 |
Histocompatibility Antigens Class II/biosynthesis | 6 | 13.0 |
Immunomagnetic Separation | 8 | 7.0 |
Isoantigens/immunology | 4 | 4.0 |
Cyclic AMP/metabolism | 2 | 0.0 |
Dinoprostone/*pharmacology | 2 | 3.0 |
Receptors, Immunologic/physiology | 3 | 2.0 |
Antibiotics, Antineoplastic/therapeutic use | 2 | 11.0 |
Cell Adhesion Molecules/blood | 2 | 6.0 |
*Chromosomes, Human, Pair 21 | 2 | 1.0 |
*Chromosomes, Human, Pair 8 | 3 | 1.0 |
Cytarabine/therapeutic use | 3 | 7.0 |
Leukemia, Myelocytic, Acute/*genetics | 2 | 1.0 |
*Translocation, Genetic | 12 | 1.0 |
Bucladesine/pharmacology | 5 | 2.0 |
Feasibility Studies | 2 | 0.0 |
Macrophages/*pathology | 7 | 13.0 |
Tumor Markers, Biological | 7 | 1.0 |
Cell Adhesion/physiology | 6 | 2.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/antagonists & inhibitors | 2 | 9.0 |
Streptococcus pneumoniae/immunology | 2 | 9.0 |
Transfection/immunology | 2 | 4.0 |
Mice, Inbred CBA | 2 | 0.0 |
Diet | 2 | 0.0 |
Leukocytes/drug effects/*physiology | 3 | 25.0 |
Neutrophils/drug effects | 4 | 7.0 |
Cell Division/drug effects/physiology | 4 | 1.0 |
Cyclins/metabolism | 3 | 0.0 |
P-Glycoprotein/*biosynthesis | 2 | 6.0 |
Autoantigens/*immunology | 2 | 1.0 |
Germany/epidemiology | 3 | 2.0 |
Infusions, Intravenous | 4 | 0.0 |
Safety | 3 | 2.0 |
Carrier Proteins/isolation & purification/*metabolism | 2 | 6.0 |
Immune Sera/pharmacology | 3 | 3.0 |
Cytokines/antagonists & inhibitors/biosynthesis | 2 | 11.0 |
Membrane Glycoproteins/pharmacology | 2 | 3.0 |
Up-Regulation/drug effects/immunology | 3 | 7.0 |
Dendritic Cells/*cytology/immunology/metabolism | 4 | 50.0 |
Antigens, CD18/physiology | 2 | 16.0 |
Mice, Knockout/genetics | 2 | 5.0 |
Shock, Septic/etiology | 4 | 28.0 |
Macrophages/*chemistry | 2 | 11.0 |
Imidazoles/pharmacology | 4 | 1.0 |
*Mitogen-Activated Protein Kinases | 5 | 1.0 |
Pyridines/pharmacology | 2 | 0.0 |
Histocompatibility Antigens Class I/*metabolism | 2 | 2.0 |
Consensus Sequence | 2 | 0.0 |
Muramidase/metabolism | 2 | 6.0 |
Proto-Oncogene Proteins c-fos/metabolism | 2 | 1.0 |
Proto-Oncogene Proteins c-jun/metabolism | 2 | 1.0 |
Fibroblasts/drug effects/metabolism | 3 | 2.0 |
Antigens, CD/*isolation & purification | 2 | 16.0 |
Macrophage Colony-Stimulating Factor/pharmacology | 13 | 19.0 |
Recombinant Proteins/immunology | 2 | 0.0 |
Antigens, CD14/analysis/metabolism | 2 | 100.0 |
Gingiva/cytology/*metabolism | 2 | 20.0 |
Bacterial Adhesion/*physiology | 2 | 9.0 |
Dogs | 4 | 0.0 |
Gram-Negative Bacteria/*physiology | 2 | 40.0 |
Gram-Positive Bacteria/*physiology | 2 | 50.0 |
Dendritic Cells/*cytology/drug effects/immunology | 2 | 20.0 |
Macrophages/*cytology/drug effects/immunology | 3 | 100.0 |
Neoplasms/*immunology | 2 | 1.0 |
Dinoprostone/biosynthesis | 2 | 3.0 |
Disease Outbreaks | 2 | 3.0 |
Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Viral Load | 2 | 0.0 |
Interleukin-1/genetics/metabolism | 2 | 11.0 |
Interleukin-6/genetics/metabolism | 3 | 12.0 |
*Transcription, Genetic | 2 | 0.0 |
Tumor Necrosis Factor-alpha/genetics/metabolism | 4 | 7.0 |
Cell Differentiation/*immunology | 2 | 7.0 |
Histocompatibility Antigens Class I/immunology | 3 | 2.0 |
Histocompatibility Antigens Class II/immunology | 4 | 2.0 |
Neoplasms/immunology | 2 | 3.0 |
Peptides/immunology | 2 | 1.0 |
Dendritic Cells/physiology | 3 | 10.0 |
Anticoagulants/*pharmacology | 3 | 3.0 |
Heparin/*pharmacology | 2 | 1.0 |
Apoptosis/drug effects/*immunology | 3 | 7.0 |
Leukocytes, Mononuclear/drug effects/*immunology | 3 | 9.0 |
Staurosporine/pharmacology | 3 | 1.0 |
Injections, Subcutaneous | 3 | 0.0 |
Fluorescein-5-isothiocyanate/metabolism | 2 | 10.0 |
Neutrophils/*immunology | 9 | 5.0 |
Receptors, Formyl Peptide | 3 | 4.0 |
Antigen-Presenting Cells/immunology | 5 | 1.0 |
Disease Susceptibility | 3 | 0.0 |
Hydrogen-Ion Concentration | 7 | 0.0 |
Phagocytes/*physiology | 2 | 20.0 |
Signal Transduction/*drug effects | 2 | 0.0 |
Skin/*cytology/immunology | 2 | 25.0 |
Umbilical Veins | 6 | 1.0 |
DNA Fragmentation | 3 | 0.0 |
Dimerization | 2 | 0.0 |
HIV Infections/*immunology | 6 | 1.0 |
*Antigens, CD34 | 2 | 2.0 |
Granulocyte Colony-Stimulating Factor/therapeutic use | 3 | 5.0 |
Stem Cell Factor | 4 | 4.0 |
Stromal Cells/cytology | 4 | 8.0 |
Antigens, Differentiation, B-Lymphocyte/analysis | 9 | 5.0 |
Antigens, Differentiation, T-Lymphocyte/analysis | 10 | 2.0 |
Bronchoalveolar Lavage Fluid/immunology | 4 | 11.0 |
CD4-CD8 Ratio | 12 | 1.0 |
CD4-Positive T-Lymphocytes/*immunology | 2 | 0.0 |
CD8-Positive T-Lymphocytes/*immunology | 2 | 0.0 |
Cell Adhesion Molecules/analysis | 15 | 9.0 |
Macrophages, Alveolar/immunology | 2 | 12.0 |
Sarcoidosis, Pulmonary/*immunology | 3 | 17.0 |
Carcinoma, Hepatocellular | 2 | 0.0 |
Carrier Proteins/*metabolism | 18 | 2.0 |
Gene Expression/genetics | 3 | 1.0 |
Glycosylphosphatidylinositols/metabolism | 4 | 7.0 |
Liver Neoplasms | 2 | 0.0 |
Heparin | 2 | 2.0 |
Leukocytes/*physiology | 7 | 12.0 |
Monocytes/physiology | 8 | 7.0 |
Gingiva/cytology | 2 | 18.0 |
Lipid A/antagonists & inhibitors | 2 | 50.0 |
Antigens, Neoplasm/*analysis | 13 | 3.0 |
Breast Neoplasms/*pathology | 3 | 1.0 |
Histocompatibility Antigens Class I/*analysis | 2 | 4.0 |
Tumor Markers, Biological/*analysis | 11 | 1.0 |
Tumor Stem Cells/immunology/*pathology | 3 | 60.0 |
beta 2-Microglobulin/analysis | 5 | 3.0 |
Antigens, CD/immunology/*metabolism | 4 | 8.0 |
Epithelial Cells | 5 | 1.0 |
Erythrocytes/metabolism | 2 | 1.0 |
Virus Replication/drug effects | 2 | 0.0 |
Glycoproteins/pharmacology | 2 | 5.0 |
Macrophages, Alveolar/drug effects/*metabolism | 2 | 20.0 |
Osmolar Concentration | 4 | 0.0 |
Phosphatidylinositols/pharmacology | 2 | 22.0 |
Phospholipase C/pharmacology | 6 | 16.0 |
Proteolipids/*pharmacology | 3 | 37.0 |
Pulmonary Surfactants/*pharmacology | 3 | 21.0 |
Temperature | 11 | 1.0 |
*Chimera | 2 | 6.0 |
HLA Antigens/genetics | 2 | 0.0 |
Y Chromosome | 3 | 3.0 |
Hyperplasia | 2 | 0.0 |
Carrier Proteins/immunology | 4 | 10.0 |
Dendritic Cells/*cytology | 12 | 21.0 |
Leukapheresis/*methods | 3 | 21.0 |
Gene Frequency/genetics | 2 | 0.0 |
Monocytes/metabolism/*microbiology | 2 | 50.0 |
Herpesvirus 8, Human/genetics/*isolation & purification | 2 | 28.0 |
Prostaglandins/biosynthesis | 2 | 7.0 |
Tetanus Toxoid/pharmacology | 2 | 8.0 |
Leukemia, Myeloid/*metabolism/pathology | 2 | 11.0 |
Neutrophils/*cytology | 3 | 15.0 |
Hypersensitivity/immunology | 4 | 10.0 |
Antigens, CD4/*immunology | 2 | 0.0 |
DNA, Neoplasm/analysis | 5 | 0.0 |
Membrane Proteins/biosynthesis | 2 | 3.0 |
B-Lymphocytes/*immunology/pathology | 3 | 7.0 |
Blast Crisis | 2 | 5.0 |
Bone Marrow/immunology/pathology | 5 | 13.0 |
*Chromosomes, Human, Pair 1 | 2 | 0.0 |
*Chromosomes, Human, Pair 19 | 2 | 0.0 |
Lipoproteins/*immunology | 2 | 11.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors | 4 | 1.0 |
Caspases/metabolism | 4 | 0.0 |
Enzyme Activation/drug effects | 11 | 1.0 |
Gram-Negative Bacteria/pathogenicity | 2 | 66.0 |
Lipopolysaccharides/*pharmacology/toxicity | 2 | 40.0 |
Clone Cells | 6 | 0.0 |
Interleukin-2/biosynthesis/pharmacology | 2 | 9.0 |
Interleukin-4/biosynthesis | 2 | 1.0 |
Receptors, Interleukin-2/metabolism | 6 | 3.0 |
HLA Antigens | 2 | 1.0 |
Inflammation/pathology | 3 | 5.0 |
Interleukin-1/analysis | 4 | 4.0 |
Exons | 3 | 0.0 |
Muramidase/biosynthesis/genetics | 2 | 50.0 |
Antigens, CD14/*analysis/metabolism | 2 | 100.0 |
Antigens, Surface/*physiology | 3 | 4.0 |
Lipopolysaccharides/metabolism/pharmacology | 5 | 27.0 |
Monocytes/immunology/*metabolism/*microbiology | 2 | 100.0 |
Antigens, CD18/*blood | 2 | 40.0 |
Receptors, IgE/*immunology | 3 | 18.0 |
Phagocytosis/*drug effects | 6 | 16.0 |
*Agriculture | 2 | 20.0 |
Reproducibility of Results | 13 | 0.0 |
Bone Marrow/*immunology/pathology | 4 | 22.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/immunology | 3 | 10.0 |
Interleukin-10/immunology/*pharmacology | 2 | 40.0 |
Blotting, Southern | 8 | 0.0 |
Disease-Free Survival | 3 | 0.0 |
Antigens, CD45/*analysis | 4 | 8.0 |
Blood Platelets/physiology | 2 | 3.0 |
Platelet Activation | 3 | 2.0 |
Lipopolysaccharides/immunology/*metabolism/pharmacology | 2 | 100.0 |
HIV-1/metabolism/*physiology | 2 | 11.0 |
*Virus Replication | 3 | 1.0 |
Signal Transduction/*drug effects/physiology | 2 | 3.0 |
Phosphatidylserines/*metabolism | 3 | 16.0 |
Antigens, CD18/*physiology | 3 | 17.0 |
Cell Membrane/physiology | 2 | 1.0 |
Endothelium, Vascular/*physiology | 2 | 1.0 |
Glycosylphosphatidylinositols/*physiology | 2 | 13.0 |
Antigens, CD4/metabolism | 2 | 0.0 |
Histocompatibility Antigens Class I/metabolism | 2 | 3.0 |
Peptidoglycan/pharmacology | 2 | 12.0 |
Anesthetics, Intravenous/*pharmacology | 2 | 50.0 |
Antineoplastic Agents/*therapeutic use | 3 | 0.0 |
Cytarabine/administration & dosage | 4 | 4.0 |
Etoposide/administration & dosage | 3 | 2.0 |
Ki-67 Antigen/analysis | 2 | 0.0 |
Receptors, Tumor Necrosis Factor/metabolism | 4 | 2.0 |
Taiwan | 2 | 1.0 |
HIV Core Protein p24/analysis | 2 | 2.0 |
HIV-1 | 2 | 1.0 |
Macrophages, Alveolar/classification/*immunology/*metabolism | 2 | 100.0 |
Interleukin-4/*pharmacology | 23 | 10.0 |
Endotoxins/*metabolism | 9 | 40.0 |
Phycoerythrin | 5 | 25.0 |
Monocytes/drug effects/*immunology/metabolism | 2 | 15.0 |
Rhodobacter sphaeroides | 2 | 66.0 |
Binding Sites/drug effects | 2 | 3.0 |
Binding, Competitive/drug effects | 2 | 3.0 |
Injections, Intravenous | 2 | 0.0 |
*Receptors, Lipoprotein | 2 | 1.0 |
Up-Regulation/drug effects/*immunology | 3 | 20.0 |
Binding, Competitive | 14 | 0.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 2 | 0.0 |
Interleukin-6/*secretion | 2 | 5.0 |
Lipid A/immunology | 2 | 40.0 |
Tyrosine/metabolism | 4 | 0.0 |
Drug Resistance, Multiple | 2 | 1.0 |
Antigens, CD/*blood | 13 | 7.0 |
Transforming Growth Factor beta/*blood | 2 | 7.0 |
Proteins/genetics | 2 | 0.0 |
Macrophages/*immunology/pathology | 2 | 20.0 |
Monocytes/*immunology/pathology | 2 | 18.0 |
LDL-Receptor Related Protein 1 | 2 | 1.0 |
Receptors, IgG/*blood | 2 | 40.0 |
*Transcription, Genetic/drug effects | 2 | 1.0 |
Zymosan/pharmacology | 4 | 4.0 |
Transcription Factors/genetics | 2 | 0.0 |
Tumor Cells, Cultured/*pathology | 2 | 10.0 |
Disease Progression | 9 | 0.0 |
Epithelial Cells/metabolism | 2 | 0.0 |
Exercise/*physiology | 6 | 1.0 |
Platelet Aggregation | 2 | 1.0 |
Respiratory Burst/drug effects | 3 | 10.0 |
CD4-Positive T-Lymphocytes/*cytology | 2 | 4.0 |
CD8-Positive T-Lymphocytes/*cytology | 2 | 10.0 |
Neutrophils/drug effects/*enzymology/immunology | 2 | 50.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors | 2 | 2.0 |
Infant, Premature | 2 | 1.0 |
*Phagocytosis | 6 | 5.0 |
Interleukin-4/*metabolism | 2 | 5.0 |
Monocytes/*pathology | 3 | 17.0 |
Dendritic Cells/*cytology/*drug effects/immunology | 3 | 60.0 |
Skin/cytology | 4 | 2.0 |
Stem Cells/cytology/drug effects | 2 | 18.0 |
Leukocytes/*pathology | 3 | 18.0 |
Pre-Eclampsia/*blood | 3 | 6.0 |
Statistics | 7 | 1.0 |
Antigens, CD14/*metabolism/pharmacology | 3 | 100.0 |
Interleukin-8/*metabolism | 2 | 3.0 |
Chromosomes, Human, Pair 21/*genetics | 2 | 2.0 |
Leukemia, Myeloid/*genetics/*immunology | 2 | 100.0 |
Receptors, Immunologic/*physiology | 4 | 2.0 |
Granulocyte Colony-Stimulating Factor/*administration & dosage | 3 | 11.0 |
Hematopoietic Stem Cell Mobilization | 2 | 2.0 |
Neutrophil Activation/*drug effects | 3 | 13.0 |
Hematopoiesis/physiology | 3 | 6.0 |
Nitroprusside/pharmacology | 3 | 4.0 |
Neoplasm Proteins/*analysis | 2 | 0.0 |
Proportional Hazards Models | 3 | 0.0 |
Hematopoiesis/*drug effects | 3 | 3.0 |
Hematopoietic Cell Growth Factors/pharmacology | 3 | 3.0 |
Antigens, CD7/analysis | 2 | 10.0 |
Oligonucleotides, Antisense/*pharmacology | 2 | 2.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 2 | 0.0 |
Lymphocyte Subsets/immunology | 2 | 1.0 |
Arthritis, Rheumatoid/*immunology/metabolism | 2 | 22.0 |
Interleukin-10/pharmacology | 2 | 2.0 |
Transforming Growth Factor beta/pharmacology | 2 | 0.0 |
Antigens, CD11c/analysis | 2 | 20.0 |
Glycophorin/analysis | 2 | 14.0 |
Laminin/analysis | 2 | 6.0 |
Serine Endopeptidases/analysis | 4 | 11.0 |
Variation (Genetics) | 4 | 0.0 |
Immunity, Mucosal | 2 | 2.0 |
Receptors, Immunologic/analysis | 6 | 6.0 |
T-Lymphocytes/cytology/*immunology | 2 | 1.0 |
Interleukin-8/*secretion | 2 | 8.0 |
Bronchoalveolar Lavage Fluid/immunology/virology | 2 | 100.0 |
Bronchoscopy | 2 | 3.0 |
HIV Infections/*complications | 2 | 0.0 |
Bone Marrow Cells/*physiology | 2 | 11.0 |
Osteoclasts/*physiology | 2 | 10.0 |
Cell Differentiation/drug effects/genetics | 2 | 3.0 |
*Chromosomes, Human, Pair 9 | 2 | 0.0 |
Osteoclasts/*pathology/physiology | 2 | 66.0 |
Lymphocytes/cytology | 2 | 2.0 |
Macrophages/*cytology/immunology/*physiology | 2 | 100.0 |
Endothelium, Vascular/*immunology | 2 | 2.0 |
Macrophage Activation/*drug effects | 7 | 20.0 |
Endothelium, Vascular/cytology | 6 | 2.0 |
Macromolecular Substances | 5 | 0.0 |
Lipopolysaccharides/blood/metabolism/*pharmacology | 2 | 66.0 |
Treponema pallidum/*immunology | 2 | 25.0 |
Carrier Proteins/pharmacology | 8 | 12.0 |
Disaccharides/pharmacology | 2 | 25.0 |
Macrophages/*drug effects/metabolism | 2 | 5.0 |
Tumor Necrosis Factor-alpha/drug effects/metabolism | 2 | 22.0 |
Arthritis, Rheumatoid/*blood | 2 | 4.0 |
Socioeconomic Factors | 2 | 1.0 |
Interferon-gamma, Recombinant/*pharmacology | 7 | 5.0 |
Thymidine/metabolism | 3 | 0.0 |
Vascular Endothelial Growth Factor Receptor-2/analysis | 2 | 14.0 |
Antigens, Differentiation, Myelomonocytic/*immunology | 13 | 30.0 |
Promoter Regions (Genetics)/genetics | 3 | 0.0 |
Sepharose | 2 | 3.0 |
HL-60 Cells/*cytology/metabolism | 2 | 66.0 |
Antigens, CD4/*metabolism | 2 | 0.0 |
Carboxylesterase | 3 | 8.0 |
HLA-DR Antigens/*metabolism | 2 | 3.0 |
Antigens, CD14/chemistry/*physiology | 2 | 100.0 |
Cytokines/*genetics | 3 | 2.0 |
Gingiva/metabolism/pathology | 2 | 50.0 |
Oligonucleotide Probes | 2 | 0.0 |
Cytomegalovirus/*physiology | 2 | 7.0 |
Arthritis, Rheumatoid/*metabolism | 3 | 5.0 |
Interleukin-1/genetics/*metabolism | 2 | 20.0 |
Synovial Fluid/metabolism | 2 | 6.0 |
Breast Neoplasms/*blood | 2 | 4.0 |
Chemotaxis, Leukocyte/*drug effects | 2 | 3.0 |
Thiobarbituric Acid Reactive Substances/metabolism | 2 | 4.0 |
Cell Movement/drug effects | 2 | 0.0 |
Endothelium, Vascular/drug effects | 3 | 5.0 |
Interleukin-8/pharmacology | 2 | 4.0 |
Immunologic Techniques | 5 | 1.0 |
Drug Resistance | 4 | 0.0 |
Enzyme Inhibitors/*pharmacology | 2 | 0.0 |
Leukemia, Promyelocytic, Acute/*pathology | 3 | 14.0 |
Monocytes | 13 | 14.0 |
COS Cells | 3 | 0.0 |
Respiratory Burst/*immunology | 2 | 28.0 |
Inflammation/*immunology | 3 | 5.0 |
Ammonium Chloride/pharmacology | 2 | 5.0 |
Immunization | 2 | 0.0 |
Neutrophils/*drug effects/metabolism | 4 | 8.0 |
Superoxides/*metabolism | 4 | 4.0 |
Mycobacterium tuberculosis/*immunology | 3 | 4.0 |
HLA-DR Antigens/analysis/blood | 2 | 100.0 |
Endothelium, Vascular/*cytology | 7 | 4.0 |
Brazil | 2 | 0.0 |
Immunity, Natural/genetics | 3 | 4.0 |
Pedigree | 3 | 0.0 |
Cell Membrane/*metabolism | 3 | 1.0 |
Glycosylphosphatidylinositols/*metabolism | 5 | 8.0 |
Leukocytes/*chemistry | 4 | 14.0 |
Immunoglobulins, kappa-Chain/genetics | 2 | 6.0 |
NF-kappa B/analysis | 2 | 25.0 |
Hemoglobinuria, Paroxysmal/*immunology | 4 | 18.0 |
Sepsis/*immunology | 2 | 40.0 |
Antigens, Bacterial/*immunology | 3 | 2.0 |
Synovial Membrane/pathology | 2 | 9.0 |
Kidney Failure, Chronic/*immunology | 2 | 14.0 |
Peritoneal Cavity/*cytology | 2 | 16.0 |
Thromboplastin/analysis | 4 | 15.0 |
*Lymphocyte Subsets | 4 | 4.0 |
Cross Reactions | 5 | 0.0 |
Epitopes | 4 | 0.0 |
Lymphoma, B-Cell/*immunology | 2 | 5.0 |
Histamine Release | 6 | 10.0 |
Cytokines/*immunology | 3 | 3.0 |
Lipoproteins, LDL/*metabolism | 2 | 1.0 |
Monocytes/chemistry/metabolism | 2 | 20.0 |
Endotoxins/*toxicity | 2 | 9.0 |
Saliva/immunology | 2 | 7.0 |
Endothelium/cytology/immunology | 2 | 25.0 |
Integrins/immunology | 3 | 14.0 |
Intestinal Mucosa/*cytology | 2 | 9.0 |
Bone Marrow Cells/pathology | 2 | 3.0 |
Plasma Cells/pathology | 2 | 5.0 |
Kidney/metabolism/pathology | 2 | 6.0 |
Carrier Proteins/*analysis | 3 | 3.0 |
Membrane Proteins/*analysis | 2 | 2.0 |
Mycobacterium/*immunology | 3 | 16.0 |
Neutrophils/*drug effects | 2 | 5.0 |
Filtration | 4 | 8.0 |
Microspheres | 6 | 3.0 |
Plastics | 3 | 9.0 |
Dendritic Cells/immunology/*metabolism | 2 | 11.0 |
Receptors, Immunologic/*genetics | 2 | 1.0 |
Receptors, IgG/*metabolism | 4 | 6.0 |
Antigens, CD18/analysis | 4 | 19.0 |
Immunotherapy/*methods | 2 | 1.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
DNA, Neoplasm/*analysis | 2 | 1.0 |
Shock, Septic/physiopathology | 2 | 22.0 |
Dendritic Cells/*pathology | 5 | 13.0 |
Lymphatic Metastasis/*pathology | 2 | 5.0 |
Antigens, CD44/analysis | 3 | 4.0 |
Colitis, Ulcerative/*immunology | 3 | 8.0 |
HL-60 Cells/cytology/*drug effects | 2 | 100.0 |
Protein Kinase C/*metabolism | 2 | 0.0 |
Calcimycin/pharmacology | 6 | 2.0 |
B-Lymphocytes/metabolism | 3 | 1.0 |
Killer Cells, Natural/metabolism | 2 | 3.0 |
Membrane Proteins/*immunology | 2 | 3.0 |
Macrophages, Alveolar/*immunology | 15 | 36.0 |
Calcimycin/*pharmacology | 2 | 6.0 |
Centrifugation | 5 | 6.0 |
Dendritic Cells/cytology/*drug effects/*immunology | 2 | 33.0 |
Antigens, CD/analysis/biosynthesis | 2 | 12.0 |
Calcitriol/*analogs & derivatives/*pharmacology | 2 | 16.0 |
Leukemia | 5 | 7.0 |
Bone Resorption | 3 | 8.0 |
Propidium | 2 | 8.0 |
Endothelium, Vascular/drug effects/*immunology | 2 | 15.0 |
Signal Transduction/*physiology | 3 | 0.0 |
*Blood Bactericidal Activity | 4 | 8.0 |
Hemoglobins/analysis | 2 | 0.0 |
*Hemolysis | 2 | 2.0 |
DNA, Neoplasm/*genetics | 2 | 0.0 |
*Tumor Cells, Cultured | 2 | 2.0 |
Antigens, CD11/*physiology | 2 | 50.0 |
Fetal Blood/immunology | 2 | 2.0 |
Lipopolysaccharides/antagonists & inhibitors/metabolism | 2 | 100.0 |
Neutrophils/*chemistry | 3 | 25.0 |
Prevalence | 3 | 0.0 |
Enzyme Induction | 6 | 1.0 |
Papio | 2 | 1.0 |
Complement 5a/pharmacology | 4 | 16.0 |
Bone Marrow/immunology | 7 | 5.0 |
*Bone Marrow Cells | 16 | 6.0 |
Indoles/pharmacology | 2 | 0.0 |
Lipoxygenase Inhibitors/pharmacology | 2 | 12.0 |
von Willebrand Factor/analysis | 4 | 1.0 |
*Receptors, G-Protein-Coupled | 2 | 0.0 |
Sialoglycoproteins/biosynthesis | 2 | 9.0 |
Cyclophosphamide/therapeutic use | 2 | 2.0 |
Liver/pathology | 3 | 1.0 |
Lymph Nodes/pathology | 5 | 1.0 |
S100 Proteins/analysis | 3 | 1.0 |
Leukemia, Myelomonocytic, Acute/*pathology | 2 | 22.0 |
Liposomes | 2 | 0.0 |
Dermatitis, Atopic/*blood | 2 | 18.0 |
Fluoresceins | 2 | 3.0 |
Lymphocytes/*metabolism | 3 | 1.0 |
P-Selectin/*physiology | 2 | 22.0 |
Immunophenotyping/*methods/standards | 2 | 50.0 |
HLA-DQ Antigens/analysis | 2 | 4.0 |
Indomethacin/pharmacology | 4 | 1.0 |
Macrophages/*cytology/immunology/physiology | 2 | 100.0 |
Cell Adhesion Molecules/biosynthesis | 11 | 13.0 |
Monocytes/*chemistry/immunology | 2 | 66.0 |
*Cell Separation | 3 | 21.0 |
Antibodies, Monoclonal/*chemistry | 2 | 5.0 |
Cattle/*immunology | 2 | 11.0 |
Receptor, Anaphylatoxin C5a | 2 | 10.0 |
Acquired Immunodeficiency Syndrome/complications/*immunology | 2 | 8.0 |
Macrophage-1 Antigen/*physiology | 3 | 15.0 |
Receptors, Leukocyte-Adhesion/*metabolism | 2 | 33.0 |
Antigens, CD/*analysis/immunology | 2 | 6.0 |
Endotoxins/*administration & dosage | 2 | 40.0 |
Histamine Release/drug effects | 3 | 12.0 |
Phagocytes/*immunology | 6 | 18.0 |
Granulocytes/cytology/drug effects | 2 | 25.0 |
Receptors, IgG/biosynthesis/blood | 2 | 100.0 |
HLA-DR Antigens/biosynthesis | 7 | 7.0 |
Fatty Acids/metabolism | 2 | 1.0 |
Nucleic Acid Hybridization | 5 | 0.0 |
Protein Kinase C/metabolism | 4 | 0.0 |
Antibodies, Monoclonal/*diagnostic use/immunology | 2 | 8.0 |
Leukemia, Lymphocytic, Acute/*immunology | 3 | 11.0 |
Lymphocyte Subsets/*immunology | 6 | 4.0 |
Bronchoalveolar Lavage Fluid | 2 | 4.0 |
Bronchoalveolar Lavage Fluid/*chemistry | 3 | 5.0 |
Inflammation/physiopathology | 2 | 3.0 |
Cell Aggregation/immunology | 3 | 15.0 |
Thromboplastin/*biosynthesis/genetics | 3 | 6.0 |
Blood Proteins/*analysis | 2 | 1.0 |
Acquired Immunodeficiency Syndrome/complications | 2 | 4.0 |
Leukocytes, Mononuclear | 2 | 4.0 |
Macrophages/metabolism/pathology | 2 | 7.0 |
Arthritis, Rheumatoid/*immunology/pathology | 3 | 9.0 |
T-Lymphocytes/physiology | 2 | 1.0 |
Acetylmuramyl-Alanyl-Isoglutamine/*metabolism | 2 | 50.0 |
Phagocytosis/drug effects/immunology | 2 | 22.0 |
Fetal Tissue Transplantation | 2 | 9.0 |
Radiation Chimera | 2 | 4.0 |
Glycosylphosphatidylinositols/*deficiency | 2 | 40.0 |
Membrane Proteins/deficiency/genetics | 2 | 18.0 |
Nitroblue Tetrazolium/metabolism | 2 | 22.0 |
Receptors, Complement/metabolism | 2 | 3.0 |
Leukemia, Promyelocytic, Acute/*drug therapy/pathology | 2 | 22.0 |
Sjogren's Syndrome/*immunology | 2 | 6.0 |
Glucocorticoids/*pharmacology | 2 | 1.0 |
Receptors, Interleukin-4 | 5 | 7.0 |
Aging/immunology | 4 | 7.0 |
T-Lymphocytes/chemistry/*immunology | 2 | 14.0 |
Ovalbumin/immunology | 2 | 4.0 |
Blast Crisis/*immunology | 2 | 50.0 |
Antigens, Neoplasm/biosynthesis | 4 | 25.0 |
Antineoplastic Agents, Phytogenic/isolation & purification/*pharmacology | 2 | 40.0 |
Neutralization Tests | 3 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 2 | 0.0 |
Ascitic Fluid/immunology | 3 | 14.0 |
Mitogens/*pharmacology | 2 | 1.0 |
Antigens, Neoplasm/*immunology | 4 | 2.0 |
Virus Replication/*drug effects | 2 | 1.0 |
Endothelium, Vascular/metabolism | 2 | 0.0 |
Cytochalasin D/pharmacology | 2 | 2.0 |
*Bone Marrow Transplantation | 3 | 0.0 |
Granulocytes | 2 | 6.0 |
Antibodies/immunology | 5 | 1.0 |
Antigens, Thy-1/analysis | 2 | 14.0 |
Luteolysis/*immunology | 2 | 100.0 |
Teichoic Acids/metabolism | 3 | 75.0 |
Cytokines/analysis/*biosynthesis | 2 | 14.0 |
Cell Wall/chemistry/immunology | 2 | 66.0 |
Chromatography, Ion Exchange | 2 | 0.0 |
Micelles | 3 | 6.0 |
Stem Cells | 2 | 1.0 |
Bacteria/isolation & purification | 2 | 12.0 |
*Bacterial Adhesion | 3 | 6.0 |
Endothelium, Vascular/*metabolism | 3 | 1.0 |
Placebos | 2 | 0.0 |
Cell Survival/physiology | 2 | 1.0 |
Arthritis, Rheumatoid/metabolism | 2 | 6.0 |
Blood Cells/*immunology | 3 | 15.0 |
Membrane Glycoproteins/biosynthesis/genetics | 2 | 4.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
Tetanus Toxoid/immunology | 3 | 3.0 |
Porphyromonas gingivalis/*metabolism | 2 | 50.0 |
Quinones/pharmacology | 4 | 2.0 |
Antigens, Differentiation, B-Lymphocyte/biosynthesis | 2 | 6.0 |
DNA Replication/drug effects | 2 | 1.0 |
Interleukin-2/biosynthesis | 3 | 0.0 |
Macaca fascicularis | 2 | 0.0 |
Blood Preservation | 2 | 2.0 |
Chickens | 2 | 0.0 |
Hematopoietic Stem Cells/cytology/*immunology | 2 | 4.0 |
Tumor Stem Cell Assay | 5 | 2.0 |
Plant Lectins | 2 | 4.0 |
Lymphoma, Large-Cell | 2 | 7.0 |
Lymphocyte Activation/physiology | 3 | 4.0 |
Helicobacter pylori/*immunology | 3 | 15.0 |
Interferon Type II/*biosynthesis/immunology | 2 | 15.0 |
Phytohemagglutinins/immunology | 2 | 4.0 |
Stereoisomerism | 2 | 0.0 |
T-Lymphocyte Subsets/*immunology | 4 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*physiology | 2 | 11.0 |
Macrophage Colony-Stimulating Factor/physiology | 2 | 25.0 |
Cercopithecus aethiops | 2 | 0.0 |
Receptors, Interleukin-6 | 2 | 2.0 |
Gene Expression/*drug effects | 3 | 1.0 |
Leukemia, Promyelocytic, Acute | 2 | 3.0 |
Acute-Phase Proteins/*physiology | 3 | 27.0 |
Lipopolysaccharides/*antagonists & inhibitors/metabolism | 2 | 66.0 |
Antigens, CD14/genetics/immunology/*physiology | 2 | 100.0 |
Autoimmune Diseases/*immunology | 2 | 1.0 |
Antigens, CD/genetics/metabolism | 2 | 3.0 |
Bone Marrow Cells/metabolism/pathology | 3 | 11.0 |
DNA/genetics | 5 | 0.0 |
Hematopoietic Stem Cells/pathology | 4 | 10.0 |
Leukemia, Lymphocytic, Acute/immunology/*pathology | 2 | 22.0 |
Gene Expression Regulation, Viral | 3 | 1.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*metabolism | 2 | 0.0 |
Protein Kinase C/physiology | 3 | 1.0 |
Chromosome Aberrations/pathology | 2 | 22.0 |
Interleukin-4/metabolism | 2 | 2.0 |
Actins/analysis | 4 | 2.0 |
Receptors, Interleukin-2/analysis | 10 | 3.0 |
Transglutaminases/analysis | 2 | 5.0 |
Monocytes/*cytology/drug effects/*metabolism | 2 | 40.0 |
Leukemia, B-Cell, Chronic/*immunology/pathology | 3 | 18.0 |
P-Selectin/analysis | 2 | 10.0 |
Hematopoietic Stem Cells/*cytology/drug effects | 3 | 4.0 |
Tritium | 2 | 0.0 |
Gene Expression Regulation/*drug effects | 8 | 1.0 |
Glycosylphosphatidylinositols/analysis | 2 | 40.0 |
Sheep/*immunology | 2 | 15.0 |
Macrophages, Alveolar/metabolism | 3 | 10.0 |
Antibodies, Monoclonal/*immunology | 14 | 1.0 |
*Cell Adhesion | 3 | 1.0 |
Cell Aggregation | 5 | 4.0 |
Lymphocyte Function-Associated Antigen-1/physiology | 2 | 4.0 |
Monocytes/*immunology/physiology | 2 | 66.0 |
Stem Cells/immunology | 2 | 6.0 |
Antineoplastic Agents, Phytogenic/*pharmacology | 4 | 2.0 |
Drug Screening Assays, Antitumor | 3 | 0.0 |
Cytarabine/pharmacology | 2 | 4.0 |
Genes, myc | 2 | 0.0 |
Adaptation, Physiological | 2 | 2.0 |
Leukocyte Count/drug effects | 2 | 1.0 |
Acrylic Resins | 2 | 8.0 |
Cellulose/*analogs & derivatives | 2 | 16.0 |
Radioimmunoassay | 5 | 0.0 |
Respiratory Distress Syndrome, Adult/*physiopathology | 2 | 33.0 |
Vascular Cell Adhesion Molecule-1/analysis | 2 | 5.0 |
Granulocyte Colony-Stimulating Factor/blood | 2 | 20.0 |
Antigens, CD/analysis/genetics | 3 | 10.0 |
Acid Phosphatase/analysis | 3 | 4.0 |
Bone Marrow/drug effects | 2 | 2.0 |
Dentin/metabolism | 2 | 25.0 |
Isoenzymes/analysis | 2 | 3.0 |
Gene Rearrangement, T-Lymphocyte | 5 | 4.0 |
Antigens, CD31 | 3 | 8.0 |
Cell Adhesion Molecules/*analysis | 2 | 1.0 |
Antigens, CD14/genetics/metabolism | 3 | 60.0 |
Antigens, CD/*analysis/*biosynthesis | 2 | 40.0 |
HLA Antigens/biosynthesis | 3 | 20.0 |
Interleukin-1/*analysis | 2 | 6.0 |
Cellulose/analogs & derivatives | 2 | 6.0 |
Buffers | 2 | 1.0 |
Antibodies, Monoclonal/*diagnostic use | 9 | 4.0 |
Antigens, Differentiation/analysis/immunology | 2 | 22.0 |
Bone Marrow/immunology/metabolism | 2 | 28.0 |
DNA/*biosynthesis | 2 | 2.0 |
Leukocytes, Mononuclear/drug effects/immunology/*metabolism | 2 | 28.0 |
Bone Marrow Transplantation | 2 | 0.0 |
*Fetus | 2 | 22.0 |
Stromal Cells/*cytology | 2 | 13.0 |
*Transplantation, Heterologous | 2 | 2.0 |
Culture Media, Conditioned | 5 | 1.0 |
Receptors, Antigen, T-Cell/genetics | 3 | 3.0 |
Receptors, Immunologic/*metabolism | 6 | 3.0 |
Granulocytes/drug effects/*immunology | 2 | 66.0 |
Antibodies, Monoclonal/therapeutic use | 2 | 1.0 |
Antigens, CD14/drug effects | 2 | 100.0 |
Bacterial Proteins/*pharmacology | 2 | 14.0 |
Interferon-alpha/*biosynthesis | 2 | 11.0 |
Kupffer Cells/physiology | 2 | 50.0 |
Immune Sera/immunology | 2 | 1.0 |
Monokines/*biosynthesis | 3 | 42.0 |
Macrophages/immunology/*pathology | 6 | 33.0 |
*Severity of Illness Index | 2 | 3.0 |
Synovial Membrane/*immunology | 3 | 8.0 |
Cell Transformation, Viral | 4 | 1.0 |
Cells, Cultured/cytology | 2 | 14.0 |
Lovastatin/*pharmacology | 2 | 9.0 |
*Immunity | 2 | 4.0 |
Blood Proteins/*immunology | 2 | 6.0 |
Bronchoalveolar Lavage Fluid/cytology/*immunology | 2 | 18.0 |
Proteins/*metabolism | 3 | 0.0 |
Leukocytes, Mononuclear/drug effects/immunology | 4 | 8.0 |
Receptors, Antigen, T-Cell/immunology | 2 | 1.0 |
Alkaline Phosphatase/blood | 2 | 1.0 |
Thrombocytopenia/etiology | 3 | 11.0 |
Vincristine/administration & dosage | 2 | 1.0 |
Neoplasm Staging | 6 | 0.0 |
Granulocytes/*cytology/immunology | 2 | 100.0 |
Arachidonic Acid/metabolism | 3 | 3.0 |
Lipopolysaccharides/*antagonists & inhibitors | 3 | 25.0 |
Endothelium, Vascular/cytology/*physiology | 3 | 4.0 |
Thromboplastin/biosynthesis | 2 | 11.0 |
Bronchoalveolar Lavage | 2 | 8.0 |
Ki-67 Antigen | 2 | 0.0 |
Labor, Premature/*immunology | 2 | 50.0 |
Platelet Membrane Glycoproteins/analysis | 2 | 2.0 |
Antigens, CD/metabolism/*physiology | 4 | 15.0 |
Lactones/*pharmacology | 2 | 6.0 |
RNA, Messenger/analysis/biosynthesis | 2 | 0.0 |
Leukocyte Count/*instrumentation | 2 | 40.0 |
Endometriosis/*immunology | 2 | 22.0 |
Macrophages, Peritoneal/*immunology | 2 | 25.0 |
Antigens, CD58 | 3 | 2.0 |
Phosphotyrosine | 2 | 0.0 |
Oligopeptides/pharmacology | 2 | 1.0 |
Leukemia, Nonlymphocytic, Acute/*genetics | 3 | 37.0 |
Leukemia, Nonlymphocytic, Acute/*pathology | 2 | 50.0 |
Bone Marrow/*immunology | 5 | 8.0 |
Antigens, CD4/*analysis | 3 | 1.0 |
Leukemia, Lymphocytic, Acute/diagnosis | 2 | 40.0 |
Phosphoric Diester Hydrolases/metabolism | 2 | 7.0 |
Antigens, Differentiation, Myelomonocytic/metabolism/*physiology | 3 | 75.0 |
Antigens, CD19 | 4 | 2.0 |
*Respiratory Burst | 4 | 20.0 |
Granulocytes/pathology | 2 | 6.0 |
Monocytes/pathology | 2 | 5.0 |
Osteoarthritis/*immunology | 2 | 18.0 |
Antigens, CD/*physiology | 26 | 8.0 |
Antigens, Differentiation, Myelomonocytic/*physiology | 24 | 77.0 |
Hemoglobinuria, Paroxysmal/blood | 2 | 28.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
*Immediate-Early Proteins | 2 | 0.0 |
Leukemia, Myeloid, Chronic/immunology/metabolism/*pathology | 2 | 66.0 |
Tumor Cells, Cultured/drug effects/immunology/pathology | 2 | 100.0 |
Antigens, Neoplasm/*biosynthesis | 3 | 9.0 |
Recombinant Proteins/therapeutic use | 2 | 0.0 |
Leukocytes, Mononuclear/drug effects | 2 | 5.0 |
Bone Marrow/metabolism | 4 | 3.0 |
Bone Marrow/immunology/*pathology | 5 | 29.0 |
Respiratory Burst/*drug effects | 2 | 7.0 |
Proto-Oncogene Proteins/immunology | 2 | 14.0 |
Receptors, IgE/genetics | 2 | 16.0 |
Biological Assay | 3 | 1.0 |
Interleukin-6/*biosynthesis/blood | 2 | 20.0 |
Leukemia, Monocytic, Acute/metabolism/*pathology | 2 | 66.0 |
Phagocytes/drug effects | 2 | 66.0 |
Leukemia, Monocytic, Acute/blood | 2 | 66.0 |
Leukemia, Myelocytic, Acute/blood | 2 | 33.0 |
Leukemia, Myelomonocytic, Acute/blood | 2 | 66.0 |
Leukemia, Promyelocytic, Acute/blood | 2 | 66.0 |
Light | 5 | 2.0 |
Calcium/physiology | 2 | 0.0 |
Antigens, Differentiation, Myelomonocytic/chemistry/*metabolism | 2 | 50.0 |
Antigens, CD/analysis/*physiology | 3 | 10.0 |
Antigens, Differentiation, Myelomonocytic/analysis/*physiology | 2 | 100.0 |
Monocytes/immunology/pathology | 4 | 26.0 |
Phospholipids/analysis | 2 | 5.0 |
*Phenotype | 3 | 1.0 |
Interferon-gamma, Recombinant/pharmacology | 2 | 1.0 |
Intracellular Fluid/microbiology | 2 | 100.0 |
Antibodies/administration & dosage | 2 | 14.0 |
Magnetics | 4 | 5.0 |
Antigens, Differentiation, Myelomonocytic/genetics/*metabolism | 2 | 40.0 |
Kidney | 2 | 0.0 |
*Sequence Deletion | 2 | 0.0 |
Cell Adhesion Molecules/pharmacology | 2 | 28.0 |
Mucins/analysis | 2 | 5.0 |
Culture Techniques/methods | 2 | 3.0 |
Growth Substances/*pharmacology | 4 | 1.0 |
Antigens, CD7 | 4 | 3.0 |
Peptide Fragments/pharmacology | 3 | 1.0 |
Cyclic AMP/*physiology | 2 | 2.0 |
Lipopolysaccharides/*antagonists & inhibitors/pharmacology | 2 | 40.0 |
Antigens, CD56 | 8 | 11.0 |
Trophoblasts/*immunology | 3 | 9.0 |
E-Selectin | 6 | 7.0 |
Vascular Cell Adhesion Molecule-1 | 6 | 7.0 |
Concanavalin A/pharmacology | 2 | 0.0 |
Oligodeoxyribonucleotides | 4 | 0.0 |
Pentoxifylline/*pharmacology | 2 | 5.0 |
Glycolipids/pharmacology | 2 | 28.0 |
Gram-Negative Bacterial Infections/etiology | 2 | 100.0 |
Lipopolysaccharides/*metabolism/toxicity | 3 | 75.0 |
Drug Tolerance | 4 | 3.0 |
Tyrosine/*metabolism | 2 | 0.0 |
Shock, Septic/prevention & control | 2 | 33.0 |
Erythrocytes/chemistry | 3 | 6.0 |
Immunohistochemistry/*methods | 2 | 2.0 |
Lipopolysaccharides/chemistry/*toxicity | 2 | 66.0 |
Receptors, Immunologic | 3 | 8.0 |
Scattering, Radiation | 4 | 3.0 |
Zinc Fingers | 2 | 0.0 |
CD4-Positive T-Lymphocytes/metabolism | 3 | 2.0 |
Ascitic Fluid/*immunology | 2 | 18.0 |
Interleukin-6/analysis | 2 | 2.0 |
Lipopolysaccharides/immunology/*metabolism | 2 | 28.0 |
Neutrophils/drug effects/*metabolism | 3 | 4.0 |
Chemotherapy, Adjuvant | 2 | 0.0 |
Drug Administration Schedule | 3 | 0.0 |
Antigens, Differentiation, Myelomonocytic/*blood | 6 | 33.0 |
beta 2-Microglobulin/metabolism | 2 | 2.0 |
Antigens, Differentiation, T-Lymphocyte/*metabolism | 2 | 1.0 |
Skin Neoplasms/*pathology | 2 | 2.0 |
Bone Marrow Transplantation/*immunology | 2 | 1.0 |
Monocytes/*drug effects/secretion | 2 | 25.0 |
Leukemia, Myelocytic, Acute/*pathology | 3 | 7.0 |
Phorbol Esters/*pharmacology | 2 | 5.0 |
Protein C/*pharmacology | 2 | 3.0 |
Graft Survival | 3 | 0.0 |
Whole-Body Irradiation | 2 | 2.0 |
Postpartum Period/immunology | 2 | 33.0 |
Up-Regulation/*immunology | 2 | 3.0 |
Membrane Glycoproteins/analysis/metabolism | 2 | 15.0 |
*Blood Transfusion, Autologous | 2 | 8.0 |
Receptors, IgG/*biosynthesis | 3 | 42.0 |
Myelodysplastic Syndromes/*complications | 2 | 18.0 |
*Blood Preservation | 2 | 3.0 |
Antigens, CD/*genetics/metabolism | 2 | 4.0 |
Antigens, CD18 | 20 | 21.0 |
Protein Kinase C/*physiology | 3 | 3.0 |
Protein-Tyrosine Kinase/*physiology | 3 | 2.0 |
DNA | 2 | 0.0 |
Hydroquinones/pharmacology | 2 | 6.0 |
Monocytes/metabolism/*pathology | 2 | 25.0 |
Pancreatic Elastase/analysis | 2 | 11.0 |
Peroxidase/analysis | 4 | 6.0 |
Tumor Cells, Cultured/metabolism/pathology | 2 | 4.0 |
Carboxylic Ester Hydrolases/analysis | 2 | 14.0 |
Hematopoietic Stem Cells/*chemistry | 2 | 7.0 |
Antigens, CD/analysis/*immunology | 2 | 5.0 |
Gram-Positive Bacteria/immunology | 2 | 40.0 |
Receptors, Immunologic/*immunology | 2 | 1.0 |
Receptors, Mitogen/metabolism | 2 | 10.0 |
Tumor Cells, Cultured/immunology/metabolism | 2 | 12.0 |
Antigens, CD13 | 15 | 27.0 |
L-Selectin | 4 | 6.0 |
Antigens, Differentiation, Myelomonocytic/physiology | 9 | 42.0 |
Cell Adhesion/*drug effects | 2 | 3.0 |
Immunoglobulin G/metabolism | 2 | 1.0 |
Receptors, Fc/physiology | 2 | 8.0 |
1-(5-Isoquinolinesulfonyl)-2-methylpiperazine | 3 | 5.0 |
Antigens, CD/physiology | 9 | 4.0 |
Genistein | 2 | 2.0 |
Isoquinolines/pharmacology | 4 | 3.0 |
Piperazines/pharmacology | 3 | 2.0 |
Tumor Cells, Cultured/*immunology | 2 | 9.0 |
*Antibody Formation | 2 | 2.0 |
Synovial Fluid/*cytology/immunology | 2 | 25.0 |
Antigens, Neoplasm/analysis | 17 | 5.0 |
Multiple Myeloma/*immunology | 2 | 5.0 |
Gene Rearrangement, B-Lymphocyte, Heavy Chain | 4 | 6.0 |
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 2 | 2.0 |
Genes, Immunoglobulin | 3 | 1.0 |
Intercellular Adhesion Molecule-1 | 18 | 7.0 |
Keratin/metabolism | 2 | 1.0 |
DNA/analysis/genetics | 3 | 2.0 |
Endotoxins/analysis/*pharmacology | 2 | 100.0 |
*Graft Rejection | 3 | 3.0 |
*Monocytes | 2 | 20.0 |
Receptors, Fc/*biosynthesis | 2 | 22.0 |
*Chromosomes, Human, Pair 7 | 3 | 1.0 |
Gene Rearrangement, B-Lymphocyte, Light Chain | 3 | 13.0 |
*Monosomy | 2 | 6.0 |
Macrophages/drug effects/*physiology | 3 | 18.0 |
Receptors, Vitronectin | 2 | 11.0 |
Leukemic Infiltration | 2 | 15.0 |
Antigens, CD11 | 21 | 25.0 |
*Blood Physiology | 2 | 7.0 |
Antigens, CD/immunology/*physiology | 6 | 18.0 |
Antigens, Differentiation, Myelomonocytic/immunology/*physiology | 5 | 100.0 |
Drug Resistance/*genetics | 2 | 4.0 |
P-Glycoprotein | 4 | 8.0 |
Gene Library | 2 | 0.0 |
Immunoglobulins, Fab/metabolism | 2 | 7.0 |
Immunoglobulins, Heavy-Chain/genetics | 2 | 1.0 |
*Bone Marrow Purging | 2 | 8.0 |
Protease Inhibitors/pharmacology | 2 | 0.0 |
Tumor Cells, Cultured/immunology/pathology | 2 | 11.0 |
Antigen-Antibody Complex/immunology | 3 | 5.0 |
Antigens/*immunology | 2 | 2.0 |
Receptors, Fc/*drug effects | 2 | 100.0 |
Antigens, CD59 | 3 | 1.0 |
Membrane Proteins/*deficiency | 2 | 25.0 |
Antibodies, Monoclonal/physiology | 2 | 2.0 |
Hematopoiesis/drug effects | 2 | 2.0 |
Killer Cells, Lymphokine-Activated/immunology | 2 | 3.0 |
Mice, Inbred DBA | 2 | 0.0 |
Hematopoietic Stem Cells | 2 | 3.0 |
Intracellular Fluid/metabolism | 2 | 1.0 |
*Peritoneal Dialysis, Continuous Ambulatory | 2 | 1.0 |
DNA Nucleotidylexotransferase/analysis | 3 | 15.0 |
Synovial Fluid/cytology/immunology | 2 | 10.0 |
Antigens, Differentiation, Myelomonocytic | 7 | 26.0 |
*Respiratory Burst/drug effects | 2 | 50.0 |
Albuterol/pharmacology | 2 | 16.0 |
Fenoterol/pharmacology | 2 | 100.0 |
Antigens, CD1 | 4 | 4.0 |
Polymerase Chain Reaction/*methods | 2 | 0.0 |
Cytoplasm/immunology | 4 | 4.0 |
Immune Tolerance/immunology | 3 | 6.0 |
Carboxylic Ester Hydrolases/metabolism | 3 | 15.0 |
Cholecalciferol/*pharmacology | 3 | 13.0 |
Glucocorticoids/therapeutic use | 2 | 2.0 |
Monocytes/*drug effects/immunology/physiology | 2 | 66.0 |
Receptor, Macrophage Colony-Stimulating Factor/genetics | 2 | 15.0 |
Microglia/*immunology | 2 | 20.0 |
*Transplantation Chimera | 2 | 10.0 |
Lipopolysaccharides/*metabolism/*pharmacology | 3 | 75.0 |
Neutrophils/drug effects/immunology/*physiology | 2 | 33.0 |
Phorbol Esters/pharmacology | 2 | 1.0 |
Saccharomyces cerevisiae/metabolism | 2 | 1.0 |
Antibody-Dependent Cell Cytotoxicity/drug effects | 2 | 11.0 |
Interleukins/*pharmacology | 3 | 4.0 |
Antigens, CD/biosynthesis/*metabolism | 3 | 27.0 |
Antigens, Differentiation, Myelomonocytic/biosynthesis/*metabolism | 3 | 60.0 |
Antigens, Differentiation, Myelomonocytic/*immunology/metabolism | 2 | 66.0 |
Interferon Type II/*biosynthesis | 2 | 1.0 |
Antigens, CD8 | 3 | 1.0 |
Cyclic AMP/biosynthesis | 2 | 1.0 |
Antigens, Differentiation, Myelomonocytic/*analysis/genetics | 3 | 100.0 |
Lymphocyte Depletion | 2 | 1.0 |
Macrophages/cytology/*metabolism | 3 | 15.0 |
Coronary Vessels/pathology | 2 | 4.0 |
*Immunohistochemistry | 2 | 2.0 |
Tonsil/pathology | 2 | 12.0 |
Bacterial Infections/*metabolism | 2 | 22.0 |
Protein Subunits/biosynthesis | 2 | 15.0 |
Membrane Glycoproteins/*blood | 2 | 3.0 |
Oxygen/metabolism | 3 | 1.0 |
Receptors, Cell Surface/*blood | 2 | 11.0 |
Tumor Cells, Cultured/pathology | 2 | 3.0 |
Arteriosclerosis/*metabolism | 3 | 4.0 |
Lymphoma, Large-Cell, Diffuse/pathology | 2 | 25.0 |
Lipoproteins, LDL/pharmacology | 2 | 4.0 |
Antigens, Differentiation, Myelomonocytic/analysis/genetics | 2 | 50.0 |
Proto-Oncogene Proteins/*genetics | 3 | 0.0 |
*Gene Rearrangement | 3 | 1.0 |
Macrophage-1 Antigen/*analysis | 2 | 28.0 |
Receptors, Calcitriol | 2 | 4.0 |
Leukocytes, Mononuclear/*chemistry | 2 | 12.0 |
Leukemia, Myelocytic, Acute/*genetics/*immunology | 2 | 100.0 |
Translocation, Genetic/*genetics | 3 | 1.0 |
Neopterin | 4 | 4.0 |
Colony-Stimulating Factors/*pharmacology | 5 | 11.0 |
Interleukin-6/*pharmacology | 3 | 1.0 |
Acute-Phase Proteins/immunology | 2 | 33.0 |
Receptors, IgE/*biosynthesis | 2 | 28.0 |
Hematopoietic Stem Cells/immunology | 4 | 5.0 |
Langerhans Cells/immunology | 2 | 5.0 |
Antigens, CD36 | 2 | 1.0 |
Antigens, CD/genetics/*physiology | 2 | 5.0 |
Antigens, Differentiation, Myelomonocytic/genetics/*physiology | 2 | 40.0 |
Endotoxins/*antagonists & inhibitors | 2 | 16.0 |
Receptors, Interleukin-1/metabolism | 2 | 8.0 |
*Lipopolysaccharides | 4 | 12.0 |
Interleukin-3/*pharmacology | 3 | 2.0 |
Heterozygote | 4 | 0.0 |
Cell Adhesion Molecules/*physiology | 4 | 3.0 |
Oligopeptides/metabolism | 2 | 3.0 |
Tuberculin/immunology | 2 | 3.0 |
Receptors, Transferrin/analysis | 3 | 8.0 |
Protein Kinase Inhibitors | 2 | 1.0 |
Antigens, CD5 | 4 | 1.0 |
Antigens, CD30 | 3 | 10.0 |
Lymph Nodes/immunology/pathology | 2 | 4.0 |
Sarcoidosis/*immunology | 2 | 9.0 |
Carrier Proteins/metabolism/*physiology | 2 | 5.0 |
Neutrophils/*cytology/metabolism | 2 | 28.0 |
Antigens, CD55 | 3 | 1.0 |
HIV-1/genetics/*physiology | 2 | 1.0 |
Gene Rearrangement | 7 | 1.0 |
Immunoglobulins, Fab/analysis | 2 | 18.0 |
Peroxidase/*analysis/immunology | 2 | 50.0 |
Bone Marrow Purging/*methods | 2 | 5.0 |
Periodontitis/*immunology/pathology | 2 | 28.0 |
*Cell Adhesion/drug effects | 2 | 9.0 |
Receptors, Complement/analysis | 2 | 3.0 |
Receptors, Fc/analysis | 8 | 13.0 |
Leukemia/*diagnosis/drug therapy/genetics | 2 | 100.0 |
*Antibodies, Monoclonal | 2 | 0.0 |
Tonsil/*cytology | 2 | 14.0 |
Receptors, Antigen, T-Cell/analysis | 2 | 1.0 |
Leukemia, B-Cell, Chronic/*immunology/*pathology | 2 | 40.0 |
Antigens, CD45 | 5 | 2.0 |
Histocompatibility Antigens/analysis | 3 | 4.0 |
Herpesvirus 4, Human | 2 | 1.0 |
Hybrid Cells | 2 | 0.0 |
Microscopy, Phase-Contrast | 2 | 2.0 |
Receptors, IgE | 4 | 6.0 |
Receptors, Immunologic/drug effects/*metabolism | 2 | 25.0 |
Fetus/cytology | 2 | 3.0 |
HLA-DR Antigens/*blood | 3 | 15.0 |
T-Lymphocytes, Helper-Inducer/immunology | 2 | 1.0 |
Monocytes/*cytology/immunology/physiology | 2 | 100.0 |
Receptors, IgG | 9 | 6.0 |
Immune System/*physiology | 2 | 3.0 |
Lymphocytes/physiology | 3 | 3.0 |
Immunoglobulin G | 2 | 1.0 |
Antigens, Differentiation/physiology | 2 | 3.0 |
Recombinant Fusion Proteins/pharmacology | 3 | 3.0 |
Lipopolysaccharides/administration & dosage | 2 | 7.0 |
Growth Substances/*genetics | 2 | 1.0 |
Leukemia, Promyelocytic, Acute/*genetics | 2 | 4.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
T-Lymphocytes/immunology/pathology | 3 | 5.0 |
Interleukin-1/immunology/pharmacology | 2 | 22.0 |
Receptors, Fc/biosynthesis | 2 | 12.0 |
Interferon Type II/physiology | 2 | 2.0 |
Immunoglobulins/genetics | 2 | 5.0 |
Leucine | 2 | 4.0 |
Leukemia, Lymphocytic, Acute/*immunology/mortality | 2 | 66.0 |
MAP Kinase Signaling System/drug effects | 3 | 3.0 |
Mothers | 2 | 2.0 |
Arthroplasty, Replacement, Knee | 2 | 33.0 |
Antigens, Neoplasm/physiology | 2 | 33.0 |
Up-Regulation/physiology | 2 | 1.0 |
Receptors, Fc | 2 | 13.0 |
RNA/biosynthesis | 2 | 2.0 |
Neprilysin | 4 | 5.0 |
Hematopoietic Stem Cells/cytology/metabolism | 2 | 8.0 |
HIV Seropositivity/*immunology | 2 | 2.0 |
Cell Membrane/chemistry/immunology/ultrastructure | 2 | 100.0 |
Antigens, Differentiation, T-Lymphocyte/immunology | 2 | 1.0 |
Cell Transformation, Neoplastic/drug effects/pathology | 2 | 50.0 |
Lymphocyte Function-Associated Antigen-1 | 3 | 3.0 |
Granulocyte-Macrophage Colony-Stimulating Factor | 6 | 7.0 |
Cytokines | 2 | 1.0 |
Phagocytosis/physiology | 2 | 6.0 |
Macrophage Colony-Stimulating Factor | 2 | 18.0 |
Interferon Type I/pharmacology | 2 | 4.0 |
HLA-DQ Antigens | 2 | 6.0 |
Macrophages/cytology/*physiology | 2 | 15.0 |
Antibody-Dependent Cell Cytotoxicity/*drug effects | 2 | 14.0 |
Receptors, Fc/*analysis | 2 | 9.0 |
Epitopes/analysis | 2 | 0.0 |
Macrophage-1 Antigen | 2 | 4.0 |
Dendritic Cells/cytology/immunology/*transplantation | 2 | 100.0 |
Stem Cell Transplantation/*methods | 2 | 11.0 |
Receptors, CXCR4/metabolism | 2 | 1.0 |
Antigens, Surface/genetics/metabolism | 2 | 15.0 |
Lasers | 2 | 1.0 |
Monocytes/cytology/*drug effects/immunology | 2 | 28.0 |
Ascitic Fluid/cytology | 2 | 10.0 |
Complement Activation | 2 | 0.0 |
Receptors, Complement/*metabolism | 2 | 1.0 |
Interleukin-4 | 3 | 3.0 |
Collagen/*metabolism | 2 | 1.0 |
Phagocytes/drug effects/*immunology | 2 | 66.0 |
Antigens, Differentiation/*immunology | 3 | 2.0 |
Receptors, Cell Surface/*analysis | 2 | 1.0 |
*Adaptor Proteins, Signal Transducing | 2 | 0.0 |
Allergens/*immunology | 2 | 2.0 |
Gene Duplication | 2 | 1.0 |
*Chemotaxis, Leukocyte | 2 | 2.0 |
Interleukin-8/*blood | 2 | 5.0 |
Antigens, CD14/biosynthesis/metabolism | 3 | 75.0 |
Antibody Formation | 2 | 0.0 |
Complement 1q/immunology | 2 | 13.0 |
*Immunophenotyping/methods | 2 | 28.0 |
Dactinomycin/metabolism | 2 | 25.0 |
HIV-1/*immunology/pathogenicity | 2 | 18.0 |
Luminescent Proteins/metabolism | 2 | 0.0 |
Lipids/metabolism | 3 | 0.0 |
CD40 Ligand/pharmacology | 2 | 7.0 |
Antigens, CD34/biosynthesis | 2 | 2.0 |
Epithelial Cells/cytology | 2 | 2.0 |
Ergocalciferols/*pharmacology | 2 | 100.0 |
Membrane Glycoproteins/*analysis/genetics/physiology | 2 | 66.0 |
Protein Transport | 2 | 0.0 |
Receptors, Cell Surface/*analysis/genetics/physiology | 2 | 50.0 |
Amniocentesis | 2 | 2.0 |
Amniotic Fluid/chemistry/*immunology | 2 | 66.0 |
Chorioamnionitis/*immunology/microbiology | 2 | 66.0 |
Pregnancy Complications, Infectious/*immunology | 2 | 9.0 |
Fimbriae, Bacterial/*physiology | 2 | 22.0 |
Mitogen-Activated Protein Kinases/physiology | 2 | 1.0 |
Neisseria meningitidis/*pathogenicity | 2 | 50.0 |
Antigens, CD11b/analysis | 2 | 25.0 |
Gram-Positive Bacteria/*immunology | 2 | 22.0 |
Polymyxin B/metabolism | 2 | 100.0 |
Cryptorchidism/*metabolism/pathology | 2 | 28.0 |
Endothelial Cells/cytology/metabolism | 2 | 12.0 |
Fucose/biosynthesis | 2 | 33.0 |
Galactosamine/biosynthesis | 2 | 33.0 |
Galactose/biosynthesis | 2 | 33.0 |
Glycoconjugates/*biosynthesis | 2 | 25.0 |
Lectins | 2 | 2.0 |
Leydig Cells/cytology/metabolism/pathology | 2 | 33.0 |
Medical Illustration | 2 | 22.0 |
N-Acetylneuraminic Acid/biosynthesis | 2 | 28.0 |
Oligosaccharides/*biosynthesis | 2 | 14.0 |
Sertoli Cells/cytology/metabolism/pathology | 2 | 33.0 |
Spermatocytes/cytology/metabolism | 2 | 15.0 |
Spermatogenesis/physiology | 2 | 6.0 |
Testis/cytology/*metabolism | 2 | 11.0 |
Protein Subunits | 2 | 0.0 |